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Abstract
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder that affects over 6
million people worldwide. Despite being the most common movement disorder in the U.S., there is still no
effective treatment for halting the progression of disease. While generally considered a sporadic and
idiopathic disorder, a number of mutations in genetic loci causal for PD have provided valuable insight
into the etiology of disease. Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are the single
most common cause of both familial and sporadic forms of PD. LRRK2 is a large 2527‐amino acid protein
with several distinct domains: leucine-rich repeats, Ras-like GTPase domain, C-terminal of ROC (COR)
domain, serine/threonine kinase domain, and WD40 repeats; however the understanding of LRRK2
function or how its aberration may lead to disease is still rudimentary. In 2006, we identified and
characterized 3 patients with the G2019S LRRK2 mutation; however this search was limited to a few
sequenced exons. An expanded screen identified 2 new patients with LRRK2 mutation, and the clinical
and neuropathological findings for all these patients are provided herein. A novel system to express and
purify the full-length protein with active in-vitro kinase activity revealed that the most common disease
causing alteration (G2019S) markedly increases kinase activity. This highlighted overactive kinase activity
as a possible intervention point for its aberrant effects. Screening for molecular inhibitors of kinase
activity identified several compounds (Gö6976, K252a, and staurosporine) that share a basic
indolocarbazole structure, which act as potent inhibitors of LRRK2 at low nanomolar concentrations.
Increased kinase activity in the absence of outside factors is unlikely to account for the pathogenicity of
the G2019S mutation. A more careful analysis of LRRK2 kinase activity revealed that this mutation,
relative to the wildtype and other pathogenic mutations, may act in a novel pathway leading to disease by
disrupting LRRK2 sensitivity to manganese kinase inhibition. Furthermore, based on kinetic data, we
propose a novel hypothesis that LRRK2 may act as a cellular sensor of manganese levels, and disruption
of this function may contribute to disease.
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ABSTRACT
THE PATHOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF
LEUCINE-RICH REPEAT KINASE 2 IN PARKINSON’S DISEASE
Jason P. Covy
Advisor:
Benoit I. Giasson Ph.D.

Parkinson’s disease (PD) is a debilitating and progressive neurodegenerative disorder that
affects over 6 million people worldwide. Despite being the most common movement
disorder in the U.S., there is still no effective treatment for halting the progression of
disease. While generally considered a sporadic and idiopathic disorder, a number of
mutations in genetic loci causal for PD have provided valuable insight into the etiology of
disease. Mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are the single
most common cause of both familial and sporadic forms of PD. LRRK2 is a large
2527‐amino acid protein with several distinct domains: leucine-rich repeats, Ras-like
GTPase domain, C-terminal of ROC (COR) domain, serine/threonine kinase domain, and
WD40 repeats; however the understanding of LRRK2 function or how its aberration may
lead to disease is still rudimentary.
In 2006, we identified and characterized 3 patients with the G2019S LRRK2 mutation;
however this search was limited to a few sequenced exons. An expanded screen identified
v

2 new patients with LRRK2 mutation, and the clinical and neuropathological findings for
all these patients are provided herein. A novel system to express and purify the fulllength protein with active in-vitro kinase activity revealed that the most common disease
causing alteration (G2019S) markedly increases kinase activity.

This highlighted

overactive kinase activity as a possible intervention point for its aberrant effects.
Screening for molecular inhibitors of kinase activity identified several compounds
(Gö6976, K252a, and staurosporine) that share a basic indolocarbazole structure, which
act as potent inhibitors of LRRK2 at low nanomolar concentrations.
Increased kinase activity in the absence of outside factors is unlikely to account for the
pathogenicity of the G2019S mutation.

A more careful analysis of LRRK2 kinase

activity revealed that this mutation, relative to the wildtype and other pathogenic
mutations, may act in a novel pathway leading to disease by disrupting LRRK2
sensitivity to manganese kinase inhibition. Furthermore, based on kinetic data, we
propose a novel hypothesis that LRRK2 may act as a cellular sensor of manganese levels,
and disruption of this function may contribute to disease.
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CHAPTER ONE

GENERAL INTRODUCTION
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1.

Parkinson’s Disease

Parkinson’s disease (PD) is the most prevalent movement disorder in the United States
(190). It affects over 6 million people worldwide, and is the second most common
neurodegenerative disorder after Alzheimer’s disease (104, 292). PD primarily affects
those over the age of 55, and the incidence of disease sharply rises after the age of 65
with as many as 50,000 new cases identified each year in the United States (236).
The disease was first described in 1817 by James Parkinson in a paper entitled “An Essay
on the Shaking Palsy”, and his clinical observations still serve as the basis for disease
classification. PD presents as a broad clinical spectrum with the cardinal symptoms of
trembling at rest, rigidity, bradykinesia (slowness of movement), postural instability, and
a therapeutic responsiveness to L-dopa, the precursor of dopamine (292). A definite
diagnosis can only be confirmed by pathological post-mortem analysis (104), as a
number of other closely related neurological disorders (termed Parkinsonisms) present
with similar PD-like symptoms.

Pathologically, PD is characterized by a loss of

(primarily dopaminergic) neurons in the substantia nigra pars compacta (SNpc) with
alpha-synuclein positive proteiniacous inclusions, known as Lewy bodies (LBs) and
Lewy neurites (LNs), present in some of the surviving neurons (58, 92, 93). During the
normal aging process, approximately 0.1-0.2% of the 400,000 dopaminergic neurons in
this area are lost per year, however, in the case of patients with PD, this rate is greatly
accelerated (40, 327).

Symptoms of the disease manifest when ~70-80% of these

neurons have been lost (63, 252). Currently, the causes and mechanisms of the selective
and accelerated loss of cells in the SN remain unclear, and no cure for PD exists.
2

1.1

Pharmacology and Anatomy of the Nigrostriatal System Relevant to PD

The progressive degeneration within the substantia nigra (SN) and subsequent loss of
dopaminergic output to the striatum is the major factor contributing to the disruption of
motor control in PD. The SN, caudate nucleus, putamen, globus pallidus (GP), and
subthalamic nucleus (STN) are the five major nuclei of the basal ganglia, which,
alongside the thalamus, receive and process input and provide feedback to the cerebral
cortex for the generation and initiation of voluntary movement.
The principal circuit associated with the basal ganglia is a loop projecting from the
cerebral cortex to the basal ganglia, to the thalamus, and back to the cortex (Figure 1-1).
These connections may be accomplished through two overlapping but distinct circuits:
the direct and indirect pathways. These pathways have competing effects on movement,
and the balance between them is involved in establishing and regulating tone. The direct
pathway facilitates movement and projects from the cortex to the striatum (the caudate
nucleus and the putamen), then to the internal segment of the GP (GPi), before
proceeding to the thalamus, and back to the cortex.

The indirect pathway inhibits

movement and also projects from the cortex, but goes to the external segment of the GP
(GPe) followed by the STN before connecting to the GPi to complete the loop to the
thalamus and cortex.

Axons leaving the striatum and GP use γ-aminobutyric acid

(GABA) as a neurotransmitter to make inhibitory synapses.

Pallidal neurons are

tonically active, therefore inhibiting parts of the thalamus.
The SN projects to all areas of the striatum in a point-to-point fashion by way of very fine
axons, and cells within the ventrolateral tier of SN pars compacta (SNpc), which project
3

to the dorsal putamen, are those predominately involved in motor coordination. This area
of the SNpc degenerates earlier and to a greater extent than other regions within the SN,
and destruction of this nigrostriatal pathway is the major factor causing the disruption of
motor control in PD. The SN pars reticulata (SNr) utilizes GABA while the SNpc uses
dopamine as its neurotransmitters. The SNpc projects to the striatum, exciting some
striatal neurons through D1 and D5 receptors, and inhibiting others through D2-D4
receptors. The striatum and STN both project to the SNr, which projects inhibitory
synapses to the thalamus. Loss of dopamine input to the basal ganglia from the SNpc
causes increased inhibition of the ventral anterior nucleus of the thalamus, which sends
excitatory glutamatergic projections to the motor cortex, leading to hypokinesia.
Supplementing the loss of dopamine with the dopamine precursor L-dopa remains the
mainstay for therapy.

4

Figure 1-1. Neurochemical pathways of the basal ganglia involved in PD. (Left) The neuroanatomy of
the basal ganglia. Areas of degeneration are colored in yellow. (Right) The neurocircuitry of the basal
ganglia’s direct and indirect pathways are both represented. Excitatory synapses are denoted by black
arrows, while inhibitory synapses are denoted by red arrows.

2.

Figure adapted from Lozano et al (190).

Pathogenesis of PD

PD is primarily considered a sporadic and idiopathic disorder. An early study examining
the concordance rates of PD in 19,842 monozygotic and dizygotic male twins bolstered
this point of view when genetic factors played were found to play no major role in
causing typical PD (313). Generally, PD was believed to be caused by environmental
factors or toxins; a view that was greatly strengthened in 1982 through the discovery of a
small number of PD cases reported in a younger cohort of patients (191). Upon close
investigation of these patients, it was found that they all had contracted PD through use of
a tainted source of synthetic heroin. A faulty step in the purification process led to the
byproduct 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which was found to be
a selective neurotoxin for dopaminergic neurons.
2.1

Mitochondrial Damage
5

MPTP is metabolically converted by glia into the active metabolite MPP(+) (246, 272).
Attributed to its structural similarity to dopamine, MPP(+) is a selective substrate for the
dopaminergic transporter, and upon uptake by dopaminergic neurons, it can inhibit
complex I of the electron transport change, resulting in a modest decline of ATP and the
generation of reactive oxygen species (ROS) (80, 189, 301). As neurons are highly
metabolically active, mitochondrial impairment can be devastating to their function.
Furthermore, the mitochondria is a key area for regulation of apoptosis and cell survival
(188, 247).
Rotenone, an insecticide that also inhibitrs complex 1, has been shown to cause selective
loss of dopaminergic neurons in the SNpc, alpha-synuclein positive fibrillar inclusions,
and behavioral changes consistent to PD upon chronic intravenous administration in rats
(although, in this model, the depletion of striatal neurons and development of tau-positive
inclusions in cortical neurons have also been reported, inconsistent with PD) (22).
However, a more recent mouse model with a disruption in the gene for mitochondrial
transcription factor A (Tfam) in dopaminergic neurons more closely resembles the
etiological progression of PD (100).

This conditional knockout has reduced

mitochondrial DNA expression and respiratory chain function in midbrain dopaminergic
neurons, intraneuronal inclusions and dopamine cell death, and adult onset impairment of
movement.

6

2.2

Environmental Risks and Toxins

The greatest risk factor for PD is age (226, 238, 330). As previously stated, nigrostriatal
loss of neurons is about 0.1-0.2% per year, however this number increases with age (40).
Outside of this common risk factor, there are a number of other not-so-common factors
that confer increased risk of Parkinsonism and PD. These range from rare insecticides
like paraquat, to more ubiquitous metals such as manganese (16, 181, 312).
The pesticide paraquat has some structural similarity to MPTP, and has been shown in
rats to cross the blood brain barrier and to lead to nigral dopaminergic cell demise (37).
The metabolism of paraquat leads to the production of reactive semiquinones and ROS,
which can induce oxidative stress and damage to the cell (227, 228) (discussed further
below). Manganese is an essential trace mineral necessary for normal development and
biological function (277). It is mainly taken in through the diet, and toxic levels are
usually not reached unless individuals experience dramatic reductions in excretion due to
liver failure (177); however, overexposure has been found in miners and welders (59,
268). Manganese causes preferential damage to the gloubus pallidus, which may be due
in part to the ability of manganese to activate this area’s glutamatergic machinery, which
may potentiate overall manganese cytotoxicity (14, 335). Manganese can initiate
apoptosis by disrupting the mitochondria, where it is rapidly taken up within the cell
(103).

Here, it can promote disruption of complex I, calcium accumulation and

subsequent activation of the permeability transition pore, and activation of caspase 3
(278). Furthermore, manganese may provide a more selective threat to dopaminergic

7

neurons as the dopamine transporter may also be involved in the accumulation of
manganese (8, 85).
2.3

Oxidative Stress

Post-mortem analysis of PD brains show increased lipid peroxidation, oxidative
modifications to proteins and DNA, depletion in levels of antioxidants such as
glutathione, and high levels of iron (71, 289); all markers of oxidative stress.
Dopaminergic neurons may already be subject to higher levels of oxidative stress from
the auto-oxidation and catabolism of dopamine, which produces electrophilic
semiquinones and quinones (90, 162). Monoamine oxidase, which is involved in the
breakdown of dopamine and other bicyclic amines, produces H202 as a normal by-product
of its metabolic process. Additionally, the auto-oxidation of dopamine into melanin can
produce reactive oxygen species (20, 128).
2.4

Ubiquitin Proteasome System

Protein deposits are common to many neurodegenerative disorders, and are usually the
result of decreased solubility, improper protein folding, and/or dysfunction in protein
clearance by the ubiquitin proteasome system (UPS) (237). The main function of the
UPS is to identify, ubiquitinate, and proteolytically degrade intracellular proteins (44,
333). Failure to do so causes protein accumulation which may lead to toxicity and
ultimately cell death (126). Within the context of PD, the proteinacious inclusions
known as LBs are rife with polyubiquitinated proteins, suggesting an inability of the
proteasome to degrade these proteins (319). Within the SN of PD patients, reports have
shown that enzymatic activity at the level of the proteasome is impaired compared to
8

controls, as well as other brain regions, and there appears to be a selective loss of 26/20S
proteasome alpha-subunits (229, 230). ATP is required for the proper assembly and
function of the 26S proteasome complex (144), and both the 26S and 20S are selectively
vulnerable to oxidative stress (38). Altogether, mitochondrial deficits in complex I and
the generation of ROS both present problems for the UPS, making this a key area
affected in PD.
2.5

Alpha-Synuclein: The First Link to Protein Dysfunction and Disease

A number of protein candidates have been associated with PD, however the most well
known and prominent is the synuclein protein. Synuclein was originally identified in
1998 from Torpedo californica (221), and its name was derived at the time from its
apparent localization to the nuclear envelope of neurons as well as presynaptic nerve
terminals. There are three members of the synuclein family of proteins: alpha-, beta-, and
gamma-synuclein. They range in weight from 14-20 kDa, however the alpha and beta are
more closely related than the gamma-synuclein (46).
Alpha-synuclein is a 140 amino acid protein with three distinct regions: an amphiphatic
N-terminal region, a central hydrophobic region, and a highly acidic and proline-rich
region. The protein is natively unfolded and assumes a random-coil formation in the
cytosol, but will adopt a secondary structure upon binding to the membrane, or during the
process of aggregation (64, 83, 341).

Shortly after PD associated mutations were

identified in alpha-synuclein (discussed below), an antibody developed against the
protein showed positive staining in LBs and LNs.(298, 299) It soon became clear that
alpha-synuclein was the main component of these pathological hallmarks, and the
9

polymerization of soluble alpha-synuclein into amyloid fibrils form the main structures of
these cellular inclusions (161, 325).
In an environment of oxidative stress, alpha-synuclein can undergo several posttranslational modifications that influence aggregation: tyrosine nitration, methionine
oxidation, and dopamine adduct formation (106, 184, 348). Oxidative cross-linking at
tyrosine residues can form alpha-synuclein dimers, which could be toxic in cellular
models (151, 185, 352). Little is known of the actual role alpha-synuclein plays within
the central nervous system, although it has been implicated in the function of the Golgi
apparatus, vesicle trafficking, and SNARE complexes as a molecular chaperone (2, 49,
317). Deletion of alpha-synuclein in mice does not lead to disease, thereby suggesting a
toxic gain of function for the protein itself, however even more controversial is the extent
that the alpha-synuclein proteinacious inclusions may play in PD; whether it is an active
toxin, a saving sponge, or just a passive artifact of another pathological pathway.
Regardless of the role, alpha-synuclein has a major presence in the pathology and
possibly pathogenesis of disease.
2.6

The Tau protein in PD

Tau is another dominant protein found in protein aggregates that are associated with
neurodegenerative disorders (196). Tau is part of the microtubule-associated protein
(MAP) family whose main function is to modulate the stability of microtubules. In
neuronal cells, tau expression is highest in the axons of neurons, however low levels can
also be detected in oligodendrocytes and astrocytes. Tau acts to assemble and stabilize
tubulin monomers into microtubules, and is important in axonal extension, transport of
10

vesicles and organelles along microtubules, and morphogenesis (51, 281).

Like

synuclein, tau can aggregate to form intracellular and extracellular protein inclusions, and
is a pathological hallmark in a variety of disorders including Alzheimer’s disease,
frontotemporal dementia, and Pick’s disease. In regards to PD, tau pathology has been
found in some LBs of cases with idiopathic PD (11), as well as other Parkinsonisms such
as progressive supranuclear palsy and corticobasal degeneration (300). In vitro, alphasynuclein and tau synergistically act to promote the fibrillization of each other (107), and
alpha-synuclein can bind to tau to stimulate tau phosphorylation by protein kinase A
(163).

In vivo, mice expressing the aggregate enhancing A30P mutation of alpha-

synuclein accumulate hyperphosphorylated tau suggestive of an early or pre-aggregated
form, concomitant with alpha-synuclein aggregation (94).

Together, these findings

suggest that alpha-synuclein may interact with tau to cause pathological changes in
disease.

3.

Genetic findings in Parkinson’s disease

The discovery of various gene defects associated with PD has revolutionized the
mechanisms of disease pathogenesis. Since the previously mentioned twin study, a
number of specific genetic candidates have shed light on potential molecular pathways
leading to degeneration and malfunction of the nigrostriatal pathway. Linkage studies
have implicated components of protein overexpression leading to aggregation, alongside
dysfunction of the ubiquitin proteasome pathway exacerbating issues of protein
misfolding and accumulation, in addition to genes involved in oxidative stress, post11

translational modification, and metal homeostasis. 5-10% of patients with PD are known
to have a monogenic form of the disease, and at least 15 genetic loci have been linked to
PD, of which 10 have been mapped to a specific gene (Table 1-1) (197, 344).
Locus
(gene)
PARK1/
PARK4
SNCA
PARK2
PARKIN

Map
Position
4q21

Protein

Putative function

Inheritance pattern

alpha-synuclein

6q25–
q27

parkin

Presynaptic protein,
neurotransmission, vesicle
recycling
Ubiquitin E3 ligase, has
neuroprotective function

PARK3?

2p13

sepiapterin reductase

AD/EOPD with rapid
progression and
dementia, sporadic
AR/juvenile and EOPD
with slow progression,
dystonia; sporadic
AD/LOPD, dementia

PARK5
UCH-L1

4p14

PARK6
PINK1
PARK7
DJ-1
PARK8
LRRK2

1p35–
p36
1p36

ubiquitin carboxyl-terminal
hydrolase isozyme L1 (UCHL1)
PTEN-induced putative
kinase 1 (PINK1)
DJ-1

12q12

Leucine-rich repeat kinase 2
(LRR2)

PARK9
ATP13A
2
PARK10
?
PARK11
?

1p36

ATP13A2/probable cationtransporting ATPase 13A2

1p32

UPS24/ubiquitin carboxylterminal hydrolase 24
GIGYF2/PERQ amino acidrich with GYF domaincontaining protein 2
Unknown

Involved in the ubiquitindependent proteolytic pathway
Involved in regulation of tyrosine
kinase receptor signaling
Unknown

Unclear

HTRA2/serine protease
HTRA2, mitochondrial
PLA2G6/85 kDa calciumindependent phospholipase
A2
FBXO7/F-box only protein 7

Serine protease, may be involved
in mitochondrial dysfunction
Catalyzes the release of fatty
acids from phospholipids

Unclear

PARK12
PARK13

2q36–
q37
Xq12–
q25
2p13

PARK14
?

22q13.1

PARK15
?
Not
assigned

22q12–
q13
2q22–
q23

Not
assigned
Not
assigned

5q23.1–
q23.3
15q25

NR4A2/nuclear receptor
subfamily 4 group A member
2
SNCAIP/synphilin-1
POLG/DNA polymerase
subunit gamma-1

Involved in biosynthesis of
tetrahydrobiopterin (BH4)
Ubiquitin hydrolase
Mitochondrial S/T-protein kinase,
has neuroprotective function
Chaperone, antioxidant,
neuroprotective, RNA binding
Protein kinase, protect cells from
stress-induced mitochondrial
dysfunction
Lysosomal ATPase
Probable cation-transporting

Involved in the ubiquitindependent proteolytic pathway
Probable nuclear receptor. May
function as a general coactivator
of gene transcription
Interact with alpha-synuclein,
substrate of parkin, part of LBs
Mitochondrial DNA polymerase
catalytic subunit
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AD/LOPD
AR/EOPD with slow
progression, tremor
AR/EOPD, dystonia,
psychiatric symptoms
AD/LOPD, tremor
AR/juvenile KuforRakeb syndrome,
EOPD
Unclear/LOPD
AD/LOPD

AR/juvenile,levodoparesponsive dystonia
parkinsonism
AR/EO, parkinsonianpyramidal syndrome
AD?
Unknown
AD, AR/EOPD

Table 1-1. Genetic Loci implicated in Parkinson’s disease. Known and unknown genetic loci are listed
alongside their chromosomal mapping, gene and protein product, putative protein function, and model of
genetic inheritance. Question marks indicate candidates still under investigation. AD, autosomal-dominant;
AR, autosomal-recessive; EO, early onset; LO, late onset; PD, Parkinson’s disease; PM, point mutations;
HM, heterozygous mutations. Table adapted from Shadini et al 2010 (285).

3.1

PARK1/4 : Alpha-synuclein

SNCA (PARK1:alpha-synuclein) was the first gene identified to have a causal role in PD
(264). In 1990, Golbe et al reported a large family with an autosomal dominant form of
parkinsonism: greater than 60 family members over the course of five generations with a
diagnoses ranging from diffuse LB disease to typical PD (120). In 1996, Polymeropoulos
and colleagues identified linkage to the long arm of chromosome 4 (262), and the next
year a 209g>a (A53T) mutation was identified in alpha-synuclein for this kindred
alongside three unrelated Greek families (264). Soon after, two additional synuclein
mutations were found: an A30P mutation in a German family (186), and an E46K
mutation in a Spanish family (351).
In vitro, alpha-synuclein can form fibrils similar to those seen in LBs (47, 345). Fibril
formation is characterized by a slow lag phase that is nucleation dependent, followed by a
faster elongation phase (345). The A53T and the E46K mutations have both been shown
to increase the rate of polymerization; however, the effects of the A30P mutation on fibril
formation in vitro are not consistent between studies (47, 109, 129). Regardless, these
findings implicate a link between alpha-synuclein aggregation and disease. This theory
was strengthened by the discovery that the PARK4 loci also mapped to alpha-synuclein
through its triplication in an Iowa kindred and a Swedish-American family with earlyonset Parkinsonism (87, 294), as well as duplication in three French and Italian families
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with typical disease onset (41). The dominant mode of inheritance from expansion of the
synuclein gene, paired with the greater severity and earlier onset for the triplication
versus the duplication, suggested a possible “SNCA gene dosage effect” leading to PD
(293). This theory is further bolstered by in vitro data which shows that the rate of
synuclein aggregation is concentration dependent (345). Consequently, this may explain
the pathogenicity behind the A30P mutation, as it has been proposed that this mutation’s
decreased ability to bind lipids may increase its intracellular pool, thereby facilitating
greater opportunities to aggregate (164).
3.2

PARK2: Parkin

The role of reduced protein degradation in PD was further emphasized with the
identification of mutations in genes affecting the ubiquitin proteasomal degradation
system: PARK2 (PARKIN:Parkin) and PARK5 (UCH-L1). Mutations in the PARKIN
gene were discovered in 1998, and are the most common form of recessive early-onset
Parkinsonism (225). Parkin is a 465 amino acid protein which is widely expressed in the
cell bodies of neurons in the midbrain, basal ganglia, cerebral cortex, and cerebellum,
where it functions as an E3 ubiquitin ligase (66). Traditionally, E3 ligases serve to
conjugate ubiquitin molecules to specific proteins, thus targeting them for degradation by
the proteasome (recent evidence suggests ubiquitin may also function in other various
signaling cascades) (146). In vitro, Parkin has been shown to interact with the E2
ubiquitin ligase UbcH7 and 8UbcH8 to promote ubquitination, and pathological
mutations decrease its ability to conjugate ubiquitin (287). In 2005, Wang et al found
that more than half of the 22 reported missense/nonsense mutations reduced Parkin
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solubility and increased the propensity of the protein to form aggresome-like aggregates,
suggesting a mechanism leading to its loss of function (336). In vivo, Parkin knock-out
mice show impaired mitochondrial function and increased markers of oxidative stress
linked to dysregulation of multiple proteins related to oxidative phosphorylation and
oxidative damage (253).

In 2006, several studies linked Parkin to another genetic

candidate in PD, PARK6 (ARPD; PTEN-induced putative kinase 1, PINK1) (45, 256).
3.3

PARK6: Pink1

After DJ-1, PINK1 was the third gene to be associated with autosomal recessive PD
(328). Pink1 is a 581 amino acid protein ubiquitously expressed in all brain regions in
both neurons and glia (at lower levels), and localizes predominately to the mitochondria
(27, 290). Structurally, the protein contains a mitochondrial targeting motif and a highly
conserved serine/threonine kinase-like domain capable of autophosphorylation in vitro
(326, 328).

Subsequent studies have confirmed Pink1’s ability to undergo in-vitro

autophosphorylation, and demonstrate that several pathological missense mutations
decrease kinase activity (18). While the function of this protein remains unclear, in vitro
models show that Pink1 overexpression protects against oxidative induced apoptosis
(259, 328).

In one cellular model, Pink1 protected against oxidative stress by

phosphorylating TNF receptor-association protein 1 (TRAP1) at the mitochondria (265).
Pink1 has also been implicated in the phosphorylation and regulation of the
mitochondrial protease HtrA2 (261). Through interaction with p38 and HtrA2, Pink1
may increase HtrA2 protease activity in response to stress. In vivo, Pink1 knock-out
mice suffer from elevated susceptibility to oxidative stress, increased mitochondrial
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calcium levels, loss of mitochondrial membrane potential, reduced synaptic dopamine
release and plasticity in the striatum, and reduced viability of cortical neuron cultures
(114, 175). In Drosophila, Pink1 knockouts develop fragmented mitochondrial cristae,
hypersensitivity to oxidative stress, and muscle and neuronal degeneration which can be
rescued by Parkin overexpression; however, Pink1 cannot rescue Parkin deletion,
indicating that Parkin may function downstream of Pink1 in a disease-relevant pathway
(45, 256).
3.4

PARK9: ATP13A2

ATP13A2 was first associated with Kufor-Rakeb syndrome, a recessive atypical
Parkinsonism, in 2006 (270). Splicing and deletion mutations resulting in truncated
forms of the protein were found in the original family, as well as a family from Chile. In
2007, three additional missense mutations were found: G504R, T12M, and G533R (72).
ATP13A2 is a large 1180 amino acid protein belonging to the lysosomal type 5 P-type
ATPase family of transporters. Recently, ATP13A2 has been shown to be protective
against alpha-synuclein induced toxicity in yeast, C. elegans, and rat primary midbrain
neurons (115). In addition, ATP13A2 may play a role in sequestering heavy metal ions
possibly by acting as a lysosomal transporter, as it exhibits protective affects in yeast
against a number of metals including manganese, cadmium, nickel, and selenium (115,
283). Currently, little else is known of this protein’s function.
3.5

PARK8: Leucine-Rich Repeat Kinase 2, Dardarin

Of all the genetic loci mapped to PD, the PARK8 locus has generated the most attention
due to its high prevalence in disease. In 1997, Hasegawa and Kowa reported a Japanese
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kindred with an autosomal dominant mode of PD inheritance (139), and five years later
they were able to determine linkage to the long arm of chromosome 12 (96). In 2004,
separate studies simultaneously identified the LRRK2 gene in a handful of other families
responsible for the PARK8 loci (250, 355). Since then, over 75 sequence variations in
the gene have been found, and it is regarded as the most common known cause of
familial and sporadic cases of PD (60).
The gene for LRRK2 spans ~7.5Mb and contains 51 exons. It encodes a large 2,527
amino acid protein with multiple complex domains, including N-terminal leucine-rich
repeats, a GTPase ROC (Ras of complex proteins) domain followed by COR (C-terminal
of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) catalytic
domain, and C-terminal WD40 repeats (Figure 2) (224). Early studies reported the
presence of ankyrin domains located in the N-terminal portion of the protein; however,
later modeling studies do not support their existence (219). Regardless, there are a
number of sequences unique to LRRK2 found throughout the N-terminal portion of the
protein that are conserved across species.
The characteristic ROC and COR domains of LRRK2 make it a member of the ROCO
protein family, alongside LRRK1, MFHAS1/MASL1, and DAPK1, which are found in
humans (Figure 1-2) (219). At least 40 other ROCO proteins have been identified in
eukaryotes and prokaryotes, and have been shown to play a role in cytokinesis, cell
polarity, and chemotaxis (1, 31, 32, 121).
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Figure 1-2. Human ROCO proteins. Schematics to scale for each of the ROCO proteins expressed in
humans with functional domains labeled. LRR, leucine-rich repeat; ROC, Ras of complex protein; Cor, Cterminal of ROC; Kin, kinase; WD40, WD40 repeat; D, death domain.

4.

The Role of LRRK2

Currently, little is known of the biological function of LRRK2. Multiple studies have
attempted to elucidate its physiological binding partners, pathological kinase substrates,
nucleotide binding activity, and signaling pathways; and while a substantial amount of
information has been reported, a significant number of these findings seem to contradict
each other.

However, despite these inconsistencies, a general role for LRRK2 is

beginning to emerge.
4.1

Expression and Localization

Expression of LRRK2 has been examined at the mRNA and protein level with some
minor differences. LRRK2 is found in numerous tissues including the lungs, heart, liver,
kidney, spleen, testes, and brain (Figure 1-3) (105, 205, 215). Within the CNS, LRRK2
mRNA expression is found in most regions including those affected in PD. A common
finding among in-situ hybridization studies utilizing rodent, primate, and human brain, is
the high levels of mRNA expression in dopaminoreceptive areas directly related to the
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pathogenesis of PD (101, 232). Particularly high expression is found in the cerebral
cortex (pyramidal projection neurons and various interneurons throughout most layers),
olfactory tubercle, and the striatum (output projection neurons, medium-sized spiny
neurons) (101, 291).

Medium expression levels have also been identified in the

cerebellum and hippocampus, and similar results have been obtained at the protein level
(137, 148, 234).

Figure 1-3. Biochemical characterization of LRRK2 protein in human and mouse tissue. (A) (Left)
Coomassie-stained gel showing the expression of recombinant His-tagged human LRRK21245-2527 protein
(~145kDa) as indicated by the arrow. (Right) Western blotting analysis showing that LRRK2 antibody
AP7099b specifically detects LRRK2 protein and some breakdown products. (B) Immunoblot analysis with
rabbit anti-LRRK2 antibody AP7099b detecting LRRK2 in postmortem human brain cortex (Hu)
(~250kDa) and as multiple species between approximately 120 to 130kDa. In various freshly dissected
mouse tissues (Cx = cortex; Ht = heart; Kd = kidney; Lv = liver; Lg = lung) and in HEK293T cells,
LRRK2 is predominantly expressed as an ~250kDa protein. Figure adapted from Giasson et al (105).

Initial studies had failed to identify LRRK2 mRNA in dopaminergic neurons themselves,
specifically within the SN (101, 232). However, late in 2006, a number of new LRRK2
antibodies allowed for the detection of moderate levels of LRRK2 immunoreactivity
within the SN (149, 316). Soon thereafter, Higashi and colleagues utilized mixed 35S19

labeled oligionucleotides, in lieu of the 33P-labeled methods used previously, and were
subsequently able to detect low levels of mRNA expression within the SN (148), and this
finding has since been confirmed in several other studies (137, 291, 316). Besides
differences in methodologies, it has been suggested that discrepancies in detecting
LRRK2 in the SN may result from the instability of LRRK2 mRNA, its short half-life, or
its transportation to distal sites within nigral dopaminergic pathways (149). In addition,
at the protein level, LRRK2 may have a long half-life in this population of neurons thus
requiring low levels of mRNA.
4.2

Kinase Domain Activity

Aberrant protein phosphorylation is a common finding in a variety of neurodegenerative
disorders. Alongside Pink1, LRRK2 is one of two kinases implicated in monogenetic
forms of PD. Within the family of human ROCO genes, kinase domains can be found in
LRRK1, LRRK2, and DAPK1. The DAPK1 kinase domain bears closest resemblance to
the calcium/calmodulin-dependent kinase (CAMK) family, while both LRRK genes were
classified within the tyrosine kinase-like (TKL) sub-family, with LRRK2 bearing closest
homology to the mitogen-activated protein kinase kinase kinase (MAPKKK) family (32,
219) and the receptor-interacting protein kinase (RIPK) family (130).
The study of LRRK2 kinase activity has been complicated by the varied complex
domains and overall size of the protein. As such, most studies to assess biochemical
activity have relied on smaller truncated versions, while only a few have successfully
utilized the full-length protein for qualitative analysis. The first obstacle in assessing the
kinase activity of LRRK2 was identifying a substrate. Luckily, it was found that LRRK2
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has the ability to autophosphorylate (117, 342). Sites of autophosphoyrlation within the
kinase domain have been suggested to take place on residues T1967, T1969, T2031,
S2032, and T2035 (residues in bold have been confirmed in at least 2 or more studies)
(116, 134, 167, 203, 213) and can occur in a cis or trans manner (134, 213).
Autophosphorylation appears to be critical for subsequent kinase activity and proper
dimerization of LRRK2 (213, 284), and conversely, some kinase inhibitors have the
ability to disrupt this dimerization (284).
In addition to autophosphorylation, myelin basic protein (MBP) has proven to be a well
tolerated generic substrate, illustrating LRRK2’s ability to phosphorylate targets beside
itself. To extend the identification of kinase substrates of LRRK2 towards physiological
targets, Jaleel and colleagues utilized a kinase substrate tracking elucidation (KESTREL)
screen of brain tissue from rodents. In doing so, they were able to identify moesin (for
membrane organizing extension spike protein), a member of the ezrin, radixin, moesin
(ERM) family of proteins (160). ERM proteins crosslink actin filaments with membranes,
and contain the following domains: an N-terminal globular FERM domain, and extended
alpha-helical domain, and a charged C-terminal domain (36). This protein family has
been shown to be involved in cell shape, growth, and motility (89). Since its initial
discovery as a LRRK2 substrate in 2007, only one study from 2009 has been able to
show physiological evidence linking the ERM protein family to LRRK2 (255). Therein,
primary neurons cultured from G2019S LRRK2 transgenic mice showed increased
numbers of pERM-positive and F-actin enriched filopodia, which coincided with
retardation of neurite outgrowth.

Regardless of whether moesin is a physiological
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substrate, the conserved sequence surrounding the phosphorylation motif in the ERM
family was synthesized into a peptide and termed LRRKtide (RLGRDKYKTLRQIRQ).
This peptide is specifically and robustly phosphorylated by LRRK2 in vitro (53, 160),
and has become the standard substrate for biochemical testing.
Because LRRK2 bears sequence homology to the MAPKKK family, attempts have been
made to identify potential substrates within the mitogen-activated protein kinase (MAPK)
cascade.

The MAPK cascade is a three-tiered signaling pathway beginning with

extracellular stimulation of MAPKKKs. Upon stimulation, they will phosphorylate a
MAP kinase kinase (MAPKK), which will then go on to phosphorylate a MAPK: signal
transducing enzymes that regulate diverse cellular responses (173, 307). MKK3/6 and
MKK4/7 were found to be mildly phosphorylated by LRRK2 in vitro at residues
necessary for their activation of c-JUN and p38 respectively (118). This finding was
subsequently replicated for MKK3, 6, and 7, albeit weakly, but not for MKK4 (153).
Regardless, in both events, there has been no discernable difference in MKK
phosphorylation states in vivo associated with LRRK2 mutation.
Recent studies in Drosophila initially indicated that 4E-BP (eukaryotic initiation factor
4E (eIF4E)-binding protein) was a potential substrate for LRRK2 (157, 308). eIF4E
binds to capped mRNA species and promotes their translation, while binding of 4E-BP
inhibits eIF4E and therefore represses translation (334). In this vein, LRRK2 would
phosphorylate 4E-BP (at T37/T46), which would then recruit other kinases to
phosphorylate the protein at secondary sites (S65/S70) thereby activating 4E-BP and
repressing translation (130). Recently, Kumar and colleagues attempted to replicate the
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phosphorylation of 4E-BP by LRRK2, and found that levels of 4E-BP phosphorylation
were extremely weak, even lower than autophosphorylation of LRRK2 (187).
Furthermore, they showed that the 4E-BP phosphorylation state in HEK cells stably or
transiently expressing LRRK2 is unaffected. Therefore, the authenticity of 4E-BP as a
physiological kinase substrate remains in question.
Qing and colleagues recently proposed that alpha-synuclein is phosphorylated by LRRK2
at S129 (267). As mentioned previously, alpha-synuclein is known to be phosphorylated
in LBs, and some studies suggest that phosphorylation at S129 is the dominant
modification in LBs (9, 95, 125). Unfortunately, we and many other groups have been
unable to replicate this finding. The original study relied on crude cellular extracts which
may contain a number of contaminating kinases known to phosphorylate synuclein at
S129 (casein kinase-2, G-protein coupled receptor kinase-2,-5 and polo-like kinases), and
they failed to provide a kinase-dead version of LRRK2 to bolster confirmation of direct
phosphorylation of alpha-synuclein. Like 4E-BP, the validity of alpha-synuclein as a
direct substrate for LRRK2 is questionable at best.
4.3

ROC Activity: GTP Binding and GTPase Activity

The ROC domain of LRRK2 shares closest sequence homology to the Ras/Rab-related
small GTPase family (219). This subfamily of GTPases is known to be involved in cell
growth, differentiation, vesicle and membrane trafficking, vesicle formation, and
membrane fusion (122, 303, 304). These GTPases are generally activated by the binding
of GTP and deactivated by its subsequent hydrolysis to GDP, a process facilitated by
guanine exchange factors (GEFs) and GTPase-activating proteins (GAPs), respectively
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(17, 30). Due to the requirement of these GEFs and GAPs, measuring GTP/GDP binding
and GTPase activity in vitro can be difficult. The first study to examine LRRK2 guanine
nucleotide binding and enzymatic activity metabolically labeled transiently transfected
non-neuronal (HEK 293) and neuronal (Neuro-2A) cells (159) and found that LRRK2
was capable of binding both GTP and GDP; however, LRRK2 recovered from cells
persisted only in the GTP bound state. While the majority of GTPases usually exist in
the GDP-bound state, there are a few that remain preferentially bound to GTP (e.g. DiRas) (182). Deficiencies in GTPase activity usually account for preferential binding to
GTP, and here, it was concluded that LRRK2 lacked the ability to hydrolyze GTP.
Subsequent studies of the GTPase domain found that this enzymatic activity is present,
however it was very weak (201). The rate limiting step was shown to be the release of
GDP, and the kcat for the hydrolysis of was reported in two studies as ~0.025min-1 (136,
205) and a third study at ~0.23sec-1 (210).
Given that both the GTPase and kinase domain are active in LRRK2, it is not surprising
that a functional link exists between the two domains. Mutating the K1347 to A in the
guanine nucleotide phosphate-binding loop (P-loop) prevents GTP/GDP from binding
(201, 296, 342).

As a result of this mutation, levels of autophosphorylation and

phosphorylation of MBP are drastically decreased, suggesting that an active GTPase
domain (or one bound to GTP/GDP) is required for functional activity. Conversely,
binding of GTP or non-hydrolyzable GTP within the ROC domain stimulates LRRK2
kinase activity (159, 296, 343).
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Despite the ROC domain’s ability to function in the absence of an active kinase domain,
the ROC domain itself contains several residues proposed to be constitutively
phosphorylated

and/or

autophosphorylated

that

may

affect

GTPase

activity:

T1343/S1345, T1348/T1349, T1368, S1403/T1404, T1410, T1452, T1491, and T1503
(residues in bold have been confirmed in at least two separate studies) (116, 133, 167).
The majority of these residues cluster around the P-loop, which may indicate a possible
role for modulation of GTPase activity by phosphorylation. T1343 alongside R1398
occupy structurally equivalent positions in Ras (G13 and Q61) which are known to
interact with the gamma phosphate of GTP (70). Similarly to inactivating mutations
found at these residues in Ras, mutating these residues in LRRK2 (T1343G and R1398Q)
disrupts GTP binding and results in lowered kinase activity.

Adjacent to the

aforementioned K1347 residue in the P-loop, mutating the T1348 to N (mimicking the
Ras S17N inactivating mutation found in a conserved S/T residue of GTPases) also
results in the ablation of kinase activity (159). Currently, how these phosphorylation
sites may affect endogenous kinase activity is unknown, but this data strengthens the role
for the GTPase domain’s regulation of LRRK2 kinase activity.
Aside from enzymatic activity, it has also been shown that the ROC domain is sufficient
for dimerization of truncated and full-length forms of LRRK2 (70, 134, 176, 206). Coimmunopreciptation of differentially tagged LRRK2, yeast two hybrid assays, native
PAGE, and gel filtration analyses support the ability for LRRK2 to interact with itself
and form dimeric as well as oligiomeric structures in vitro and in cell culture systems.
Published in 2007, the crystal structure of the ROC dimer shows a complex degree of
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interaction between the two monomers (70). Each monomer contains 5 alpha-helices and
6 beta-strands with loops in-between distributed through the head, neck and body
domains. The head domain and first half of the neck domain from one monomer interacts
with the body domain of the other monomer.

Berger recently demonstrated that

compared to the monomer, the LRRK2 dimer binds GTP more efficiently, has increased
kinase activity, and is enriched in the membrane (21). This study also found that the
membrane-bound pool of LRRK2 had a 30% decrease in phosphorylation levels
compared to the cytostolic pool.
In addition to self-interaction, the Roc domain is sufficient for interaction with a variety
of binding partners. The carboxy terminus of HSP70-interacting protein (CHIP), which
acts to ubiquitinate and direct LRRK2 for degradation by the proteasome (76, 179),
interacts with LRRK2 through the ROC domain. In addition, the ROC domain can pull
down ribosomal binding proteins S8 and L3, as well as alpha/beta tubulin heterodimers
(102). In primary hippocampal neurons, endogenous LRRK2 has been shown to
colocalize with alpha/beta-tubulin colocalize in the cell body and along neuronal
processes (102), and this finding has also been seen in HEK293 cells for beta-tubulin
(117). A functional interaction has been shown in-vitro through the phosphorylation of
beta tubulin by LRRK2 (112), although this has not yet been replicated. However, this
same study found that LRRK2 knockout mice display a ~33% reduction in
phosphorylated beta-tublin compared to wild-type controls.

Multiple lines of other

evidence suggest a role for LRRK2’s interaction with the cytoskeleton. For example, in
cellular models of primary neurons, RNAi knock down of endogenous LRRK2 causes a
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significant increase in process length, while disruption of the ROC domain leads to
shortened processes (214).
4.4

Non-Enzymatic LRRK2 Domains

There are three defined non-enzymatic domains that have consequential effects on
LRRK2 functionality. Starting from the C-terminus, the first of these is the WD40
domain.

First described in 1986, WD40 domains have been implicated in signal

transduction, pre-mRNA processing, and cytoskeleton assembly (91, 295, 305). The
LRRK2 WD40 domain is a notable point of divergence between the LRRK1 homologue,
and therefore may be critical for its unique function. Recently, T2483 in the WD40
domain was identified as a site of autophosphorylation (116), and deletion of this domain
results in a loss of autophosphorylation as well as decreased phosphorylation of MBP
(134, 156, 160, 165). In addition, the WD40 deletion disrupts the ability of LRRK2 to
dimerize (134, 165), while its addition to the ROC-Cor-Kinase fragment strengthens
dimerization (134).

Deletion of the WD40 domain in the zebrafish homologue for

LRRK2 (zLRRK2) results in loss of dopaminergic neurons in the diencephalon alongside
defects in locomotion (286). Aside from dimerization, the WD40 domain may also play
a critical role in functionally linking LRRK2 to other proteins.
LRRK2 associates with a number of membrane-bound organelles and vesicular
membranous structures, including lipid rafts and the outer membrane of the mitochondria
(24, 140, 342). In yeast, another similar complex of proteins known to associate with the
mitochondrial membrane is the Fis1.Mdv1.Dnm1 complex (240).

Dnm1 (dynamin-

related GTPase) can interact with the outer membrane of the mitochondria, but is only
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stably retained through interaction with the WD repeat containing adaptor protein Mdv1,
where further interaction with Fis1 triggers mitochondrial fission. Given that LRRK2 has
both a GTPase and WD40 repeat region, the WD40 domain may play a similar role,
linking LRRK2 and other protein interactors at the level of the membrane.
While a number of studies implicate the ROC domain’s ability to regulate kinase activity,
it is unclear how this signal is transduced to the kinase domain. When the structure of the
ROC domain was published in 2008, there was note of a strong intrinsic interaction
between the ROC and Cor domains, stronger than that of the ROC domain and full-length
LRRK2 (70).

It has therefore been hypothesized that upon activation of the ROC

domain, the Cor domain may act as a molecular hinge to facilitate the dimerization and
subsequent autophosphorylation of the kinase domain (70, 331). The structure of the
highly conserved Roc-Cor domain of the C. tepidum prokaryotic homologue of LRRK2
was published in 2008 and showed that this region contained two subdomains connected
by a long, slightly flexible single polypeptide chain (127). This study proposed that
instead of the ROC domain, dimerization is facilitated through the COR domains’
interaction at its C-terminal subdomains. In this formation, the ROC domains partake in
a more freely mobile state.
In addition to dimerization, the Cor domain has been implicated in an interaction between
LRRK2 and Parkin (297).

Co-expression studies of these two proteins in HEK293T

cells show that both proteins CO-IP with each other, and this interaction is facilitated
through the Cor domain of LRRK2 and the RING2 domain of parkin. Co-expression also
resulted in an increase in cytoplasmic aggregates that contain LRRK2 and enhanced their
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ubiquitination; however, unlike CHIP, there is no direct evidence that parkin is involved
in the ubiquitination of LRRK2. It is unclear why the amount of ubiquitinated aggregates
increased, however the coexpression of LRRK2 increased the autoubiquitination activity
of parkin 25-fold, which may lead to the overall stimulation of the ubiquitin proteasome
pathway.
While few functional findings have been reported for the leucine-rich repeat (LRR)
region of LRRK2, Shin and colleagues discovered that this portion of the protein interacts
with Rab5b (288). Rab5b is a small GTPase involved in synaptic function by modulating
endocytosis of synaptic vesicles (202). Its interaction with LRRK2 is isoform specific as
neither Rab5a nor Rab5c interact with the protein. Both proteins were detected in the
soluble synaptosome fraction (although LRRK2 was also found in the cytosol and other
membrane fractions) in rat cortex, and both proteins co-localized in the cell body and
neurites as well as with presynaptic vesicle markers (synaptobrevin-2, synaptophysin) in
rat hippocampal neurons. Functionally, LRRK2 overexpression causes a decrease in the
rate of synaptic vesicle endocytosis, and this effect can be rescued by the expression of
both wildtype and a constitutively active Rab5b, but not a dominant negative form.
Deletion of the LRR region does not appear to affect localization of transiently expressed
LRRK2 in SH-SY5Y cells, however it does prevent toxicity by disrupting its ability to
induce caspase 3 activation and nuclei condensation (156). In vitro kinase activity is not
affected by the loss of this domain, and so presumably this effect is mediated by the LRR
region’s direct interaction with signaling partners in the apoptotic cascade.
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These

interactions may be regulated by a narrow stretch of serine residues directly preceding the
LRR region, which is a site of high constitutive phosphorylation (116).

5.

Mutations in LRRK2 and its Link to PD

Autosomal dominant missense mutations in the gene for LRRK2 are the most common
known cause of PD (110, 249, 355). Over 75 sequence variations have been identified in
LRRK2, of which at least 5 missense mutations are considered definitely pathogenic
(R1441C/G, Y1699C, G2019S, and I2020T), and 2 others are considered increased risk
factors for disease (R1628P, G2385R) (60). Understanding how these mutations lead to
the dysfunction of LRRK2 may shed new light on potential pathways in the progression
of PD.
5.1

The Pathology of Cases with LRRK2 Mutation

To date, a relatively low number of cases have come to autopsy with mutations in
LRRK2. A wide range of pathological phenotypes have been reported in these patients,
ranging from classic degeneration of the SN with traditional Lewy pathology similar to
presentation in idiopathic cases of PD, to pure nigral degeneration with a lack of Lewy
pathology and the presence of tau neurofibrillary tangles (NFTs) (56, 62, 96, 98, 99, 105,
111, 113, 172, 222, 269, 276, 346, 347, 355). These varying pathologies are even present
with patients who carry the same mutation (Figure 1-4): in three patients with the
G2019S mutation, two (Patient A and B) demonstrated classic PD with LBs, while the
third (Patient C) had a paucity of Lewy pathology. Patient A also displayed LBs in the
limbic cortex, while patient B had concurrent neocortical senile plaques and occasional
NFTs (105).
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Figure 1-4. Histological characterization of patients with LRRK2 mutations. (A, B) Staining for alphasynuclein in the SNpc of Patient A using antibody Syn 505 demonstrating the presence of classic LBs
(arrow) and cytoplasmic alpha-synuclein inclusions (arrowheads) in dopaminerginergic neurons containing
neuromelamine. An alpha-synuclein spheroid is indicated by an asterisk in B. (C) Cortical LBs stained with
anti–alpha-synuclein antibody Syn 505 in the cingulated cortex of Patient A. (D) A neurofibrillary tangle
(NFT) (arrow) and tau-positive dystrophic neurites within a senile plague (SP) in the hippocampus of
Patient B stained with anti–tau antibody 17026. (E) The staining pattern of LRRK2 depicted with rabbit
anti–LRRK2 antibody AP7099b. Note the intense staining in Purkinje neurons and their processes. (inset)
Immunofluorescence analysis showing the cytoplasmic pattern of HA-tagged LRRK2(1245-2527)
expressed in HEK293T (green) and DAPI staining of the nuclei (blue). (F, G) Dystrophic neurites in the SN
of Patient C displaying accumulation of LRRK2 as stained with the rabbit anti–LRRK2 antibody. Scale bar
= 40μm. Figure from Giasson et al (105).

A paucity of Lewy pathology has been reported in 1 out of 17 additional G2019S cases
(99, 269), 6 of the 8 autopsied patients from the Hasegawa and Kowa Japanense kindred
with the I2020T mutation (97, 139), the only R1441G (Basque) case autopsied (222), 2 of
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the 4 R1441C cases from the Canadian family D (74, 142, 346, 355), and 2 of the 4
Y1699C cases (172, 355). The additional neuropathological findings for these atypical
cases have been mixed.

For the 2 Y1699C cases, amyotrophy in addition to

parkinsonism was observed, and there was a presence of “ubiquitin-positive” cytoplasmic
and nuclear inclusions (355). For the R1441C mutations carried within the Canadian
family D, one of the documented cases presented tau pathology reminiscent of
progressive supranuclear palsy while another displayed nonspecific loss of dopaminergic
neurons with ubiquitin-positive inclusions in the absence of Lewy pathology (346, 355).
Despite the pleomorphy of pathological inclusions observed throughout the literature, all
cases report degeneration of the SN.
Given studies showing that LRRK2 forms aggregates in some cellular models (131,
297), several laboratories began examining LRRK2’s presence in LBs (4, 131, 148, 234,
235, 269, 353). In our initial 2006 study of the 3 G2019S patient described above, no
LRRK2 staining of LBs was observed, nor was LRRK2 found in brain Lewy inclusions
from an additional 80 patients with either classic PD (46 cases) or DLB (34 cases).
Shortly thereafter, Zhu and colleagues published a letter indicating that LRRK2 could be
found in LBs when using two newly designed antibodies by Novus Biologicals (354).
We tested these antibodies and found that their specificity was lacking (Figure 1-5), and
concluded the staining of LBs could be non-specific (55); other laboratories have
corroborated these results (280). Because we cannot account for batch differences among
commercial antibodies, we designed and developed our own. We engineered three
antibodies, one monoclonal and two polyclonal, which were very specific for the LRRK2
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protein. Using these antibodies, again, a paucity of staining was observed for LRRK2 in
LBs (340).

Regardless, a handful of studies have used the nonspecific antibodies

mentioned above to ascribe the inclusion of LRRK2 in LBs (4, 131, 148, 234, 235, 269,
353); however, staining is inconsistent and therefore inconclusive. It remains to be seen
whether LRRK2 is truly a component of Lewy pathology, but our studies indicate that it
is not.

Figure 1-5. Characterization of LRRK2 antibodies. A. Schematic of LRRK2 and its
associated domains with antibodies AT106 (Alexis Biochemicals, San Diego, CA), NB
300-267 (Novus Biologicals, Littleton, CO), NB 300-268 (Novus Biologicals), and
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AP7099b (Abgent, San Diego, CA) listed above their epitopes for LRRK2.

B.

Immunoblot analyses of high-salt extracts from the brain cortex of two healthy
individuals, (Hu-1 and Hu-2) and mouse cortex (Mo), and a RIPA-soluble extract from
HEK293T cells with various LRRK2 antibodies. Antibody AP7099b detects full-length
Lrrk2 with mobility of ~250kDa, as well as a ~130kDa breakdown product, which is due
to postmortem degradation. AT106, NB 300-267, and NB 300-268 detect a variety of
immunobands, but none that corresponds to full-length LRRK2. Figure adapted from
Covy and Giasson 2006 (55).
Mixed pathologies have also been reported in various in vivo models.

In LRRK2

knockout mice, no aberrant brain neuropathology has been found up to 2 years of age
(10, 68, 209, 323); however, significant effects have been observed in the kidney where
LRRK2 is normally expressed at high levels (~6-fold compared to the brain) (323). Loss
of LRRK2 within the kidney leads to an age-dependent increase in markers of autophagic
dysfunction (LC3-II, p62) and apoptotic cells (activated caspase-3, TUNEL positive
cells) alongside the accumulation (60-fold over wild-type) and aggregation of alphasynuclein and other ubiquitinated proteins. Conversely, in the brains of A53T alphasynuclein transgenic mice, which normally develop an age-dependent fragmented Golgi
apparatus in neurons that correlates with an increase in the somatic accumulation of
alpha-synuclein, genetic ablation of LRRK2 serves a protective role by preventing these
abnormalities, while transgenic expression of human LRRK2 exacerbates the phenotype
(209). Conflicting pathology has also been found in Drosophila models. It was first
reported that the loss of dLRRK (the Drosophila orthologue for both LRRK1 and
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LRRK2) resulted in severely impaired locomotor activity and reduced tyrosine
hydroxylase (TH) immunoreactivity of DA neurons (195). Shortly thereafter, a handful
of studies reported that loss of dLRRK had no effects on TH immunoreactivity of DA
neurons, however overexpression of dLRRK, human LRRK2, or their mutant forms can
cause dopaminergic neuron degeneration and locomotor dysfunction (157, 211, 242,
332).
5.2

LRRK2 Kinase Domain Mutations are the Most Prominent Cause of PD

The I2020T mutation within the kinase domain was among the earliest missense
mutations identified in LRRK2 (97). Soon thereafter, additional mutations were found,
including the most prevalent mutation just adjacent to this residue: G2019S (166). The
G2019S mutation is reportedly responsible for 0.6-1.6% of sporadic PD and 2-8% of
familial PD cases (50). In certain ethnicities, such as North African Arabs and Ashkenazi
Jews, the G2019S mutation is an even greater factor contributing to PD (22-41% of
individuals with disease) (198, 199, 248). A large case-control study from 2008 found
that the G2019S accounts for more than 85% of patients carrying a mutation within
LRRK2 (141). Given that the pathological G2019S mutation lies within the activation
loop of the kinase domain, much attention has been directed towards understanding how
aberration of kinase activity may lead to disease.
5.3

The Common G2019S Pathological Mutation Increases Kinase Activity

Initial in-silico studies suggested that the G2019S mutation may increase LRRK2 kinase
activity (3). Given that no nonsense mutations of the protein had been identified, this
model coincided nicely with a gain-of-function for LRRK2. Indeed, the overwhelming
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majority of studies on LRRK2 kinase activity show that the G2019S mutation increases
activity around 2-3 fold over wild-type (130).
G2019 is part of the highly conserved DFG motif in the VII subdomain of the kinase
region (138, 168), and the D residue in this motif is involved in Mg2+ binding and proper
coordination of ATP-Mg2+ in the active site (67, 170, 200, 315). The DFG motif is
located at the N-terminal hinge region of the activation loop that switches from an open
and extended conformation in the active state to a more closed conformation in the
inactive state (67, 168, 315), and this G residue is thought to play an important role in
inducing proper orientation of the D residue (183). After inactivation, the G residue
usually performs an extreme twist which disrupts its hydrogen bond to the D residue,
thereby facilitating this D residue to also to turn away from the catalytic site. The lack of
a side chain is thought to allow the G residue to make this turn with little steric hindrance.
The G2019S mutation may disrupt the ability of this movement, and could keep the D
residue positioned in the active site for longer activation periods that may also contribute
to a greater catalytic rate.
5.4

LRRK2 Kinase Activity is Linked to Neurotoxicity

While the majority of studies agree that the most common G2019S mutation increases
kinase activity, the effect of other pathological LRRK2 mutants remains unclear. For the
I2020T mutation, some studies report a modest increase (117, 157, 212, 343), a slight
decrease (160, 244), or no change in activity (7, 213). In our hands, this mutation slightly
increases activity of the full-length protein (54).

Mixed information has also been

reported for the R1441C, and Y1699C mutation (7, 54, 131, 132, 136, 160, 214, 296,
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342, 343). A caveat to these results is the wide range of techniques used: from the type
of substrate (autophosphorylation, generic proteins, synthetic peptides), to the assay
conditions (reaction temperatures, indirect phosphorylation, chosen cofactors), and even
the form of LRRK2 utilized (bacterially expressed, endogenously purified, truncated
versions). As a result, it’s difficult to interpret the varied effects on kinase activity;
however, it is still possible to examine the role the kinase domain plays in LRRK2
toxicity.
The earliest in vivo studies on the toxic effect of the G2019S were reported in Drosophila
when expressing the human form of LRRK2 (hLRRK2), however mixed results have
been reported for studies utilizing mutant dLRRK knockins as well as knock-outs. These
inconsistencies in Drosophila (as well as those seen for C. elegans models) must be
approached with caution because the single LRRK gene is not a true orthologue of the
human LRRK genes (220): similarity in hLRRK2 and dLRRK is only 38–44% (332).
While no overt pathological phenotype has been found in G2019S LRRK2 transgenic
mice up to 24 months of age, disruptions in striatal dopamine transmission have recently
been identified (204, 231, 338).

G2019S LRRK2 transgenic mice show an age-

dependent decrease in release, uptake, and overall content of straital dopamine. In
addition, G2019S LRRK2 may cause age-dependent hyperphosphorylation of tau. In
G2019S LRRK2 BAC transgenic mice aged 18–24 months, hyperphosphorylated tau at
S202/T205 and S262/S356 was observed in mice only after 6-12 months of age (233).
However, an earlier study found no changes in tau phosphorylation at S202/T205 and
S396/S404 (204), but both studies found a modest increase in tau phosphorylation when
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overexpressing wild-type LRRK2. Despite these contrasting effects, rat cortical neurons
transfected with G2019S or I2020T LRRK2, but not wild-type LRRK2 contained
spheroids in neuronal processes that stained positive for phosphorylated tau at S202
(214). These studies illustrate a possible connection between aberrant kinase activity and
tau phosphorylation in vivo.
In both neuronal cell lines and primary neuronal cultures, wild-type LRRK2 forms
aggregates in a small proportion of cells, and several pathogenic mutations (I1122V,
R1441C, Y1699C, G2019S, and I2020T) have been shown to increase its propensity to
aggregate (131, 297). When expressed in COS-7 cells, LRRK2 aggregates colocalize
with gamma-tubulin and are surrounded by vimentin, although not reactive for Lamp-1
(340). In addition, blocking the proteasome with MG132 increases the frequency and
size of LRRK2 aggregates, while treatment with the microtubule depolymerizing agent
nocodozole breaks up these large aggregates (Figure 1-6), suggesting these are the result
of aggresome formation.
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Figure 1-6.

LRRK2 aggregates in transfected COS-7 cells.

Double immunofluorescence was

performed with a monoclonal anti-V5 antibody (red) and rabbit anti-LRRK2 antibody 1181#1 (green) in
COS-7 transfected with LRRK2-V5. (A) Rare large aggregates were observed under basal conditions at 48
hours post-transfection. (B) Sixteen hours of MG132 (10µm) treatment induced aggregate formation. (C)
MG132 treatment with concomitant nocodazole prevented the formation of large, perinuclear aggregates.
Small aggregates throughout the cytosol were noted with nocodazole treatment (inset). Images are
representative of 3 independent experiments. Bar scale: 50µm; inset 25µm. Figure from Waxman et al
2009 (340).
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In addition to protein aggregation, LRRK2 pathogenic kinase domain mutations can also
cause neurodegeneration consistent with mitochondrial-dependent apoptotic cell death.
In rat primary cortical neurons, overexpression of the pathological G2019S and I2020T
LRRK2 mutants, but not wildtype LRRK2, leads to a progressive reduction of branching
and neurite outgrowth, and decreased cell survival marked by elevated levels of activated
caspase 3 (214). Reductions in neurite outgrowth have also been shown in primary
neurons from G2019S LRRK2 transgenic mice (338), and caspase 3 activation by mutant
forms of LRRK2 was replicated in a similar study using SH-SY5Y cells. Here, LRRK2
caused the release of cytochrome c, and was dependent on Apaf1 for caspase 3 activation
(156).

Another study found that LRRK2 can mediate apoptotic cell death through

interaction with the death adaptor protein FADD to recruit and activate caspase 8 (150).
There may also be an autophagic component of LRRK2 mediated cell toxicity. AlegreAbarrategui and colleagues utilized a specialized BAC-vector expressing the LRRK2
locus at low physiological levels in HEK293-FRT cells to identify the recruitment of
LRRK2 to specific membranous microdomains within multivesicular bodies (MVBs), as
well as to autophagic vacuoles (AVs) (5). Autophagic degradation of organelles can also
be found in pre-differentiated SH-SY5Y cells overexpressing G2019S LRRK2 in both
neuritic and somatic compartments (214). RNAi knockdown of components of the
autophagy system (LC3 or Atg7) prevent these effects of G2019S LRRK2 on neuronal
process length and toxicity, while treatment with an autophagy enhancing drug
(rapamycin) potentiates its effect (260).
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The aberrant effects of the pathogenic mutants of LRRK2 appear to be directly regulated
by and/or dependent on an active kinase domain. Introducing amino acid substitutions
that disrupt kinase activity (i.e. knocking out the ATP binding domain, metal cation
binding motif, or proton acceptor site) into pathological LRRK2 mutants reduce the
number of LRRK2 aggregates back towards levels of the wildtype protein (131, 297).
More importantly, in all models of LRRK2-mediated cell death discussed above,
inactivating the kinase domain negates all effects of mutant LRRK2 toxicity: neurite
branching and outgrowth is restored, markers of autophagic degradation are no longer
observed, enhanced binding of FADD is disrupted, and caspase activation is inhibited.
The dependence of all these effects on functional kinase activity highlights the critical
role this domain plays in facilitating the deleterious effects of LRRK2.
5.5

Mutations Outside of the Kinase Domain can Affect Kinase Activity

Outside of the kinase domain, the most prominent region where mutations are observed is
the ROC domain. As previously mentioned, the ROC domain is an enzymatically active
GTPase, in which the GTP bound form has a stimulatory effect on kinase activity.
Various mutations have been reported within this region; however the most notable is at
R1441. The ROC domain is capable of binding with itself, and is sufficient to pull down
full-length LRRK2; an interaction that is disrupted by the pathogenic R1441C mutation
(206). As the ROC domain dimerizes, this R residues sits between the interacting surface
of the two monomers (70), and its mutation may disrupt the stability of the ROC dimer
and subsequent enzymatic activity. Indeed, several studies have shown that pathogenic
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ROC mutations decrease GTPase activity, prolonging the protein in the GTP-bound state
(136, 201, 205).
Given that ROC mutations prolong the GTP-bound state of LRRK2, one would assume
that this mutation would result in increased kinase activity. However, as discussed
above, the experimental data on kinase activity has been mixed.

A caveat to the

discrepancy may revolve around the expression and purification methodology of LRRK2.
Multiple studies have shown that intrinsic GTPase activity of the protein is weak, and
LRRK2 purified in the presence of nonhydrolyzable GTP displays increased kinase
activity compared to LRRK2 purified without (159, 205, 296, 343).

The R1441C

mutation may in fact prolong the more active GTP-bound state of LRRK2, however, if
the protein does not have access to the necessary GEFs (or is overexposed to particular
GAPs) required for proper GTP binding, it may explain some of the discrepancies.
A model of decreased GTPase activity by the mutation at R1441 leading to increased
kinase activity adheres to the similar results observed in cellular models for LRRK2
toxicity. As with the G2019S and I2020T mutants, R1441C/G LRRK2 induces caspase 3
in an Apaf1 dependent manner, decreases neurite length and branching, and coincides
with markers of autophagic degradation (156, 214). Furthermore, inactivating the kinase
domain disrupts all toxic effects of R1441C/G LRRK2 mutations, strengthening the
theory that kinase activity is required for the neurodegenerative effects of pathological
LRRK2. In vivo, R1441 LRRK2 transgenic mutations recapitulate similar symptoms of
the G2019S LRRK2 mutant, as R1441C LRRK2 knock-in mice (322) and R1441G
LRRK2 BAC transgenic (207) mice both show deficits in dopamine release. In addition,
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the SNpc of R1441G LRRK2 transgenic mice have a decrease in TH immunoreactive
dendrites as well as a decrease in average cell body size.
The WD40 domain also appears to have a direct effect on kinase activity, and as a result,
the neurotoxicity of LRRK2. Like the kinase-inactive form, mouse primary cortical
neurons transfected with LRRK2 pathological mutants lose their toxic effect if the WD40
domain is deleted (156). Examining these constructs in-vitro reveals that removal of the
WD40 domain results in disruption of LRRK2 dimerization, and a loss of
autophosphorylation (165). Not only is this domain required for kinase activity and
neurotoxicity, the R2385G LRRK2 mutation found in this region results in an increased
risk for developing PD and has recently been shown to have a slight activating affect on
kinase activity (~1.5 fold) (310). Interestingly, this mutation has a high prevalence in
Han Chinese (4-8%), while the G2019S mutation has yet to be found (6, 310, 311).
6.

Scope of this Research

The identification of genetic factors causal for PD has provided a valuable opportunity to
gain much needed insight into the etiology of this disease. Mutations in the gene for
LRRK2 are the single most common known cause of both familial and sporadic forms of
PD; however, the understanding of this protein’s function is still rudimentary and it
remains unclear how aberration of LRRK2 leads to disease. The followings aims were
developed to address these issues which represent the scope of this thesis research:
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Research Aim I
Screen for mutations of LRRK2 in patients with PD and DLB, and characterize their
neuropathological consequences.
Research Aim II
Develop an in-vitro model of LRRK2 kinase activity to assess the effects of pathogenic
mutations and identify compounds that can inhibit substrate phosphorylation.
Research Aim III
Determine a possible mechanism for the greater pathogenicity of the G2019S LRRK2
mutant versus other LRRK2 pathogenic mutations.
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CHAPTER TWO
CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF
PATIENTS WITH LEUCINE-RICH REPEAT KINASE 2
MUTATIONS

Data from this chapter was published in:
Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI (2009).
Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2
mutations. Mov Disord. 24; 32-9
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ABSTRACT
Mutations in LRRK2 are the single most common known cause of Parkinson’s disease
(PD). Two new PD patients with LRRK2 mutation were identified from a cohort with
extensive post-mortem assessment. One of these patients harbors the R793M mutation
and presented with the typical clinical and pathological features of PD. A novel L1165P
mutation was identified in a second patient. This patient had the classical and
pathological features of PD, but additionally developed severe neuropsychological
symptoms and dementia associated with abundant neurofibrillary tangles in the
hippocampal formation; features consistent with a secondary diagnosis of tanglepredominant dementia. α-Synuclein-containing pathological inclusions in these patients
also were highly phosphorylated at S129, similar to other patients with idiopathic PD.
These two PD patients also were characterized by the presence of occasional cytoplasmic
TDP-43 inclusions in the temporal cortex, a finding that was not observed in three other
patients with the G2019S mutation in LRRK2. These findings extend the clinical and
pathological features that may be associated with LRRK2 mutations.
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INTRODUCTION
Parkinson’s disease is the second most common neurodegenerative disease in the
developing world and is characterized by bradykinesia, resting tremor, cogwheel rigidity
and postural instability (104, 292). These major clinical features of PD are associated
with the loss of dopaminergic neurons in the SNpc (63, 252). In addition, postmortem
analysis of the majority of clinically diagnosed PD patients reveals intracytoplasmic
inclusions known as LBs and LNs in some of the remaining dopaminergic neurons. LBs
and LNs are formed as the result of the aberrant aggregation of the presynaptic protein
alpha-synuclein. These inclusions can also accumulate in other brain regions in PD as
well as other related neurological disorders (33, 93, 119). The presence of these
inclusions is a criterion used to differentiate PD from other disorders associated with
parkinsonism (92, 93).
Autosomal dominant mutations in the gene for leucine-rich repeat kinase 2 (LRRK2; also
known as PARK8) have been identified in a significant percentage of late-onset PD cases
(250, 355). Five missense mutations with definite pathogenicity and many other missense
mutations that are potentially pathogenic or may act as risk factors have been reported
(314). G2019S, the most common mutation, is reportedly responsible for 0.6-1.6% of
sporadic (69, 111, 166) and 2-8% of familial cases of PD (69, 73, 145, 166, 245, 251). In
some specific ethnicities such as North African Arabs and Ashkenazi Jews, the G2019S
mutation is linked to a much higher percentage (22-41%) of patients diagnosed with PD
(198, 199, 248). In addition, the penetrance for this mutation increases with age from 15-
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17% at the age of 50 years to 32-100% at the age of 80 years depending on the reported
cohort (124, 166, 199).
LRRK2 is a large 2527-amino acid protein with several distinct domains: Leucine-rich
repeat (1010-1287), GTPase (1335-1504), COR (1517-1843), kinase (1875-2132) and
WD40 repeat (2231-2276) (Fig. 2-1A) (355). The understanding of the biological
function of LRRK2 is still rudimentary. The majority of patients with LRRK2 mutations
present with classical PD with LBs (105, 111, 254, 276), but some have Parkinsonism
without Lewy pathology (97, 99, 105), and diverse clinical and pathological findings
have also been reported in others (269, 347, 355). Hence, the clinical and pathological
features of two patients, one patient with the R793M mutation and another with a novel
L1165P mutation in the Leucine-rich domain, are described.
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Figure 2-1. Identification of patients with LRRK2 mutations and sequence alignment of amino acids
surrounding the mutations. (A) Schematic representation of the LRRK2 protein with major domains. The
locations of the R793M, L1165P, and the most common G2109S mutation are indicated. Abbreviations
used: LRR, leucine-rich repeat like domain; ROC, Ras of complex; COR, C-terminal of Roc. (B) Portion of
sequencing electropherogram showing the region of LRRK2 exon 25 in which the heterozygous
c.3494T>C, p.L1165P was identified in Patient E compared to normal sequence. The mutation is near the 3'
end of exon 25. The exon/intron junction is indicated by the dashed line. (C) Cross-species alignment of
the amino acid sequence surrounding residue L1165. (D) Cross-species alignment of the amino acid
sequence surrounding residue R793.

MATERIALS AND METHODS
Antibodies
Murine anti-α-synuclein monoclonal antibodies LB 509, Syn 514 and Syn 211 were
previously described (13, 79, 108). SNL-4 is a purified rabbit polyclonal antibody raised
against a peptide corresponding to amino acid residues 2-12 in α-synuclein (108). pSyn
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129a is novel mouse monoclonal antibody specific for α-synuclein phosphorylated at
S129 (340). Antibody 17026 is a rabbit antiserum raised against full-length recombinant
tau that detects all isoforms of tau. AP7099b is an affinity purified rabbit antibody to
LRRK2 raised against the peptide RVEKLHLSHNKLKEIPPEIG (Abgent, San Diego,
CA) (105). Anti-TAR-DNA-binding protein 43 (TDP-43) rabbit polyclonal antibody was
purchased from ProteinTech Group (Chicago, IL).
Molecular Genetic Analysis of LRRK2
Genetic analysis of LRRK2 was performed in a large cohort of neurodegenerative disease
clinical and autopsy cases, including 98 cases (78 autopsied) with PD or DLB as
previously described (43). Single nucleotide polymorphism (SNP) genotyping using
TaqMan chemistry-based allelic discrimination assay with “Assay by Design” (Applied
Biosystems, Foster City, CA) probes on an Applied Biosystems 7900 was performed for
the LRRK2 mutations: G2019S, I2020T, M1869T, R793M, and Y1699C. Appropriate
positive and negative controls were used and data was analyzed using Sequence
Detection System 2.2.1 software (Applied Biosystems) as described (88). In the PD and
LB autopsy cases, bi-directional DNA sequencing of a 251 bp product containing exon
25 was used to evaluate for the presence of the I1122V mutation which also allowed for
the identification of a novel c.3494T>C, p.L1165P (Fig. 1B) variant within the exon 25
region as described (43).

All cases with LRRK2 mutations were confirmed by bi-

directional DNA sequencing using standard methods on a CEQ8000 (Beckman Coulter).
To evaluate the novel exon 25 mutation c.3494T>C, p.L1165P, a TaqMan “Assays by
Design” allele discrimination assay was developed and performed on 366 control
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samples. The control samples were obtained from the following sources: 276 controls
from the Coriell Institute (Neurologically Normal Caucasian control panels, Camden,
NJ), 48 clinical controls (mean age 76) from the Alzheimer Disease Center at the
University of Pennsylvania, and 42 brain autopsy samples (mean age 69) with normal
pathology from the University of Pennsylvania Center for Neurodegenerative Disease
brain bank. All research activities were approved by the University of Pennsylvania
Institutional Review Board and all participants gave informed consent.
Immunohistochemistry and Immunofluorescence
The harvesting, fixation and further processing of the tissue specimens were conducted as
previously described (78). Briefly, tissue blocks were removed at autopsy and fixed by
immersion in 70% ethanol with 150mM/L NaCl or 10% buffered formalin for 24-36 hr.
Samples were dehydrated through a series of graded ethanols to xylene at room
temperature and infiltrated with paraffin at 60ºC as previously described (78). Tissue
blocks were then cut into multiple, near serial 6μm sections for immunohistochemical
staining.
Immunohistochemistry was carried out using the avidin-biotin complex (ABC) detection
system (Vector Laboratories, Burlingame, CA) and 3,3’-diaminobenzidine as described
previously with some modifications (78). Briefly, sections were deparaffinized and
sequentially rehydrated using 100-70% ethanol followed by water. Some sections were
pretreated with 88% formic acid to enhance antigen detection. Endogenous peroxidases
were quenched with 5% hydrogen peroxide in methanol for 30 min and sections were
blocked in 0.1M Tris with 2% fetal bovine serum (Tris/FBS) for 5 min. All antibodies
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were diluted in Tris/FBS. Primary antibodies were incubated overnight at 4ºC. After
washing, sections were sequentially incubated with biotinylated secondary antibodies for
1 hr and ABC complex for 1 hr. Bound antibody complexes were visualized by
incubating sections in solution containing 100mM Tris, pH 7.6, 0.1% Triton X-100,
1.4mM DAB, 10mM imidazole, and 8.8mM hydrogen peroxide. Tissue sections were
lightly counterstained with hematoxylin.
For immunofluorescence, tissue sections were re-hydrated and incubated with primary
antibodies as described above.

After washing, anti-mouse or anti-rabbit secondary

antibodies conjugated to Alexa Fluor 488 and 594 secondary were applied (Molecular
Probes, Eugene, OR). Following washing and post-fixation with formalin, sections were
cover-slipped with Vectashield with 4'-6-diamidino-2-phenylindole mounting medium
(Vector Laboratories, Burlingame, CA).

RESULTS
Genetic Analysis of LRRK2:
Among the 98 sporadic and familial PD patients screened, 4 (~4%) were identified with
the G2019S mutation (3 heterozygous and 1 homozygous). Of these, the clinical and
pathological findings for three cases have been previously reported,(105) while the fourth
was a living patient with onset of PD at age 44, a strong family history of PD, and a
homozygous G2019S mutation. Additionally, the p.R793M (c.2378 G>T) mutation was
identified in 1 PD case (described further below as Patient D). The I2020T, M1869T,
and Y1699C mutations were not identified. DNA sequence analysis of exon 25 did not
identify any I1122V mutations; however, the novel missense mutation in exon 25
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(c.3494T>C, p.L1165P) (Fig. 2-1B) was identified in one PD case (described further
below as Patient E). The L1165P mutation was absent from 366 controls tested using
TaqMan SNP analysis. Thus, overall, 5 cases with LRRK2 mutations were found in the
cohort of autopsies PD and DLB patients (5/78, 6.4%).
Clinical and Pathological Findings in Cases Harboring the R793M and L1165P
Mutations in LRRK2:
Patient D: Patient D is a woman that first manifested unexplained falls at the age of 77.
Within one year, clear evidence of Parkinsonism had developed, and she was started on
carbidopa/levodopa therapy for relief of rest tremor, rigidity and general bradykinesia.
She responded well to treatment in the early years of her illness, but she developed
slowly progressive disability and died 15 years after onsest at 92.
At autopsy, the SN and the locus coeruleus (LC) were severely depigmentated, but other
brain regions were unremarkable. Detailed histological analysis revealed abundant LBs,
LNs and α-synuclein immunoreactive spheroids in the SNpc (Fig. 2-2A, B), other brain
stem nuclei, the hippocampus and the amygdala (Fig. 2-2C), but these inclusions were
only sparsely present in the neocortex (Fig. 2-2D) with a distribution characteristic of
PD.(33, 93, 119) Neurofibrillary tangles (NFTs) and tau-positive dystrophic neurites
were moderately abundant in the hippocampal formation (Fig. 2-2E), but rare in other
brain regions. Senile plaques (SPs) were rare in all brain regions. No inclusions were
detected with antibodies specific to LRRK2.
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Figure 2-2. Histological characterization of patients with LRRK2 mutations. (A, B) Staining for αsynuclein in the SNpc of patient D demonstrating a dopaminergic neuron with multiple LBs (A) or a typical
spheroid (B). (C) Abundant LBs and LNs in the amygdala of patient D. (D) Cortical LBs in the cingulated
cortex of patient D. (E) NFTs and tau-positive dystrophic neurites in the hippocampus of patient D. (F) A
classical LB in a dopaminergic neurons in SNpc of patient E. (G) Abundant LBs and LNs in hippocampus
of patient E. (H, I) NFTs and tau-positive neurites in the hippocampus and enterhinal cortex, respectively,
of patient E. Tissue sections were stained with the following antibodies: anti-α-synuclein antibody Syn 514
(A, C, D, and G), anti-α-synuclein antibody Syn 211 (B), anti-α-synuclein antibody LB509 (F), and antitau antibody 17026 (E, H and I). Scale bar = 25 µm in A, B, D, E, F, and 50 µm in C, G, H, and I.

Patient E: This man developed the first signs of Parkinsonism at age 47, including
resting tremor, stooped posture and shuffling gait, but no sensory impairments. He was
treated with carbidopa/levodopa therapy and responded well. At the age of 56, he
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developed visual and auditory hallucinations that only partly improved following
withdrawl of levodopa therapy. His neurological condition gradually deteriorated with
the emergence of apathy, delusions, confusion, memory impairments and severe
depression. He died at the age of 81.
Postmortem examination revealed extensive loss of pigmented neurons in the SNpc and
LC without neuronal loss in other brain regions. Numerous LBs, LNs and α-synuclein
immunoreactive spheroids were found in the SNpc (Fig. 2-2F). α-Synuclein inclusions
were frequent in the amygdala and in the hippocampal formation (Fig. 2-2G) and sparse
in the neocortex. NFTs were abundant in the hippocampal formation (Fig. 2-2H, I) and
the amygdala. Tau-containing inclusions were rare in other brain regions. SPs were
infrequent in all regions of the brain. No inclusions were detected with antibodies specific
to LRRK2. The clinical and pathological features of this patient are consistent with a
primary diagnosis of PD and a secondary diagnosis of tangle predominant senile
dementia.
Phosphorylation of S129 in α-Synuclein in the Pathological Inclusions of Patients
with LRRK2 Mutations
Since the multiple functional domains and in-vitro kinase activity of LRRK2 has made
LRRK2 a prime candidate for regulating signal transductions pathways, and α-synuclein
is phosphorylated at S129 in pathological inclusions,(95) we therefore analyzed the
phosphorylation state of α-synuclein in patients with LRRK2 mutations. Using an antiphospho-S129 α-synuclein specific antibody (pSyn 129a), the vast majority of αsynuclein pathological inclusions in the brains of both patients D and E were immuno55

positive for phosphorylated Ser129 α-synuclein (Fig. 2-3). Similar phosphorylation of αsynuclein was also observed in 2 other previously described patients (105) carrying the
G2019S mutation (data not shown).

Figure 2-3. Double-labeling Immunofluorescence Analysis of α-Synuclein Phosphorylated at S129 in
Pathological Inclusions of Patients with LRRK2 Mutations. Double-labeling immunofluorescence
analysis demonstrating the presence of α-synuclein phosphorylated at S129 in the vast majority of αsynuclein inclusions in patients with LRRK2 mutations. Depicted are tissue sections from the SNpc from
patient D (A-C) and the amygdala from patient E (D-F). Panels A and D show immunostaining with the
rabbit anti-α-synuclein antibody SNL-4 (green) and panels B and E depicts staining with mouse antiphospho-S129 α-synuclein antibody pSyn 129a (red). The overlays are shown in C and F. Scale bar =
65µm.

TDP-43 Cytoplasmic Inclusions in Patients with LRRK2 Mutations
“Tau-negative, α-synuclein negative, ubiquitin-only” positive inclusions have been
reported in some patients with LRRK2 mutations (347, 355). Recently, a patient with
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frontotemporal lobar degeneration with ubiquitinated neuronal inclusions has been
reported to carry the G2019S mutation (62). Since TDP-43 has recently been identified as
a major component of ubiquitin inclusions in frontotemporal lobar degeneration (241)
and a subset of PD patients have TDP-43-containing inclusions (239), the presence of
TDP-43-positive inclusions in patients with LRRK2 mutations was ascertained.
Occasional cytoplasmic TDP-43 inclusions were observed in both patient D and E, but
only in the temporal cortex (Fig. 2-4). No similar cytoplasmic TDP-43 inclusions were
observed in the brains of the three previously reported PD patients carrying the G2019S
LRRK2 mutation (105), or an additional five sporadic PD patients analyzed (data not
shown).

Figure 2-4. TDP-43 Cytoplasmic Inclusions in Patients with LRRK2 Mutations. Staining with an
antibody to TDP43 revealed the presence of TDP-43 cytoplasmic inclusions in the temporal cortex of
patient D (A) and patient E (B, C). Aberrant cytoplasmic TDP-43 inclusions are depicted by arrows, and
normal nuclear localization is indicated by arrowheads. Scale bar = 25µm.

DISCUSSION
The identification and characterization of patients with mutations in LRRK2 is pivotal in
understanding the effects of aberrations of the various domains of this protein. Herein,
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we describe the clinical and pathological findings of two patients with missense
substitutions in LRRK2 identified from a cohort of patients with pathologically confirmed
PD and DLB. One subject (patient D) was found to harbor the R793M amino acid
substitution and presented with the typical clinical and pathological features of PD. This
variant has been previously reported in three patients with PD (2 familial and 1 sporadic),
one patient with primary progressive aphasia, and four 40-61 year old control individuals
(4 out of a total of 2065, 0.2%) (19, 43, 88, 320). The presence in a small percentage of
unaffected individuals contests the pathogenicity of the R793M substitution; however,
since these individuals are still relatively young (40-61 year old) it possible that they may
yet manifest disease with age. Like the G2019S mutation (124, 166, 199), the R793M
substitution may be associated with reduced, age-dependent penetrance, or it may confer
increased risk for expression of clinical disease, similar to the G2385R mutation (75,
309). The nature of the R793M substitution, a disruption of two highly conserved basic
residues within a stretch of hydrophobic residues (Fig. 2-1D), further suggests potential
pathogenic properties. Irrespective of the pathogenicity or risk association, this is the first
pathological characterization of a patient with the R793M variant. This patient
demonstrated the classical clinical and pathological features of PD.
The second patient (patient E) was found to have a novel mutation L1165P in LRRK2.
This patient presented with onset in middle age and had a long duration of illness (34
years). Although this patient had typical features of PD, he also became severely
demented. The abundance of tau pathology in the hippocampal formation without SPs
and concurrent dementia is consistent with a secondary diagnosis of tangle predominant
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senile dementia (also termed senile dementia with tangles). The relatively early onset of
illness in this patient and the lack of this substitution in more than 366 control patients
suggest that this mutation may be pathogenic. In addition, L1165 is highly conserved
across multiple species (Fig. 2-1C) and the L to P substitution would be predicted to
cause a dramatic structural change within the Leucine-rich domain. However, since the
function of this region in LRRK2 is unknown, the overall effect of this mutation is
unclear, and it is uncertain if the atypical pathological features of this patient are directly
associated with this amino acid substitution.

Although, it is notable that severe

neuropsychiatric symptoms also have been described in a subset of patients with the
G2019S and I2020T mutations (123, 321).
Most patients with mutations in LRRK2 present with clinical PD and have typical LB
pathology, but a subset of patients have diverse pathological findings. These differences
cannot solely be explained by the nature of specific mutations since significant
differences can be observed between patients with the same mutation. For example, while
17 of the 20 autopsied PD patients reported with the G2019S mutation have shown
classical nigral degeneration with nigral LBs (105, 111, 254, 276), three cases have
presented pathological findings indicating concurrent Alzheimer disease (105, 276). Two
patients were shown to have nigral degeneration without Lewy pathology (99, 105), and
the third lacked Lewy pathology but presented with a tauopathy with features suggestive
of supranuclear palsy and early Alzheimer disease-type pathology (269).
Atypical clinical features associated with LRRK2 mutation were first observed in the
Canadian family A with the Y1699C mutation where amyotrophy was observed in
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addition to Parkinsonism in some patients (355). The autopsies of two individuals from
this kindred demonstrate SN degeneration, a paucity of α-synuclein positive LB and LN
pathology, and the presence of “ubiquitin-positive” cytoplasmic and nuclear inclusions.
On the other hand, individuals from the Lincolnshire kindred that carry the same
mutation had clinical PD and LB brain pathology (172). Diverse pathological findings
have also been reported for the R1441C mutations carried within the Canadian family D.
Autopsies of two of the documented cases present classical α-synuclein positive LB and
LN pathology, but the third has tau pathology reminiscent of progressive supranuclear
palsy.

The fourth patient lacked Lewy pathology; however nonspecific loss of

dopaminergic neurons with ubiquitin-positive inclusions were found (347, 355).
Although α-synuclein inclusions are more frequently observed in patients with LRRK2
mutations than aggregates comprised of other proteins, all types of proteinaceous
inclusions may contribute to neuronal dysfunction. TDP-43 has been identified as a
major component within ubiquinated neuronal intranuclear inclusions of patients with
frontotemporal lobar degeneration (241). Recently, the G2019S mutation was identified
in an individual with frontotemporal lobar degeneration with ubiquinated neuronal
intranuclear inclusions (62), and these inclusions have recently been found to be
comprised of TDP-43 (241). Within the current study, histological analysis revealed
occasional cytoplasmic TDP-43 inclusions within the temporal cortex of patients D and
E. This is the first report of a histological analysis for TDP-43-positive inclusions in
patients harboring LRRK2 variants. It would be interesting to determine whether the
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“ubiquitin-only” inclusions that have been previously reported in some patients with the
Y1699C and R1441C mutations are comprised of TDP-43.
It can be surmised from the wide range of disease onset, incomplete penetrance, and
diverse pathological findings associated with LRRK2 mutations that these alterations may
render neurons more vulnerable to other insults that can result in neuronal degeneration
with or without protein aggregation. Further studies will be required to better understand
the mechanisms of neurodegeneration associated with LRRK2 mutations and the
contribution of protein aggregation.
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CHAPTER THREE
IDENTIFICATION OF COMPOUNDS THAT INHIBIT THE KINASE
ACTIVITY OF LEUCINE-RICH REPEAT KINASE 2

Data from this chapter was published in:
Covy JP, Giasson BI (2009). Identification of compounds that inhibit the kinase activity
of leucine-rich repeat kinase 2. Biochem Biophys Res Commun. 378; 473-7
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ABSTRACT
Mutations in leucine-repeat rich kinase-2 (LRRK2) are the most common known cause of
late-onset Parkinson’s disease. In this study, a novel system to purify LRRK2 was used to
characterize the specificity of this kinase and identify small compounds that can inhibit
kinase activity. The specificity of this enzyme for the phosphorylation of T558 site in
moesin was established by using a spectrum of synthetic peptides with well-characterized
kinase recognition motifs. The G2019S mutation, which is the most common disease
causing alteration in LRRK2, markedly increased the activity (~10 fold). A screen for
molecular inhibitors identified several compounds (Gö6976, K252a and staurosporine)
that share a basic indolocarbazole structure as potent inhibitors. The identification of
these compounds will be important tools to study the biological function of LRRK2 in
vivo, and can be used as starting points to generate more selective inhibitors that could
have therapeutic application in Parkinson’s disease.
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INTRODUCTION
Parkinson’s disease is the most common neurodegenerative movement disorder. The
principal pathologies of PD are the loss of dopaminergic neurons in the SNpc in addition
to the presence of intracytoplasmic inclusions known as LBs and LNs in some of the
remaining dopaminergic neurons (92, 119). The mechanism(s) and cellular insults
leading to the demise of neurons in PD are under investigation; however oxidative stress,
protein misfolding, and mitochondrial dysfunction have been implicated as factors in the
disease process (48, 65, 271).
The discovery of specific genes that can be causal of PD has provided important new
insights into the cellular pathways that are involved in the pathobiology of PD (29, 174,
263, 329).

Studies in the past few years have revealed that autosomal dominant

missense mutations in the LRRK2 gene (also known as PARK8) are collectively the
single most commonly known cause of late-onset PD (250, 355). In particular, the
G2019S mutation is the most prevalent, and is responsible for 2–8% of hereditary PD,
and 1-2% of sporadic PD cases (69, 73, 110, 111, 166, 245, 251). In North African Arabs
and Ashkenazi Jews, the G2019S has been reported to be causal of 20-40% of PD cases
(198, 199, 248).
LRRK2 is a large 2527 amino acid protein with several discrete domains that include
many leucine-rich repeats, a Ras (renin-angiotensin system) of complex (ROC) domain,
which belongs to the Ras GTPase superfamily, and a kinase domain towards the Cterminal end (110, 250, 355). In vitro, LRRK2 functions as a S/T kinase that can undergo
autophosphorylation, and can phosphorylate the generic kinase substrate myelin basic
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protein (MBP) (160, 342, 343). It was recently shown that T688 in moesin can be
phosphorylated by LRRK2 (160). The G2019S mutation appears to affect the activation
loop of the kinase domain and in some in vitro studies it results in 2-3 fold increase in
kinase activity (160, 342) which may lead to neurotoxicity (131, 296, 343). Nevertheless,
there is still limited information on the specificity of LRRK2, and inhibitors for this
kinase have not been reported. In this study we describe a novel system to purify active
recombinant LRRK2. This recombinant enzyme was used to characterize the specificity
of LRRK2 and identify small compounds that can inhibit the kinase activity. Our findings
show that LRRK2 kinase activity is inhibited by several inhibitors that share a basic
indolocarbazole structure.

MATERIALS AND METHODS
Materials
Goat anti-glutathione-S-transferase (GST) polyclonal antibody was purchased from
Amersham Biosciences (Piscataway, NJ). 1182 is a rabbit polyclonal antibody raised
against a recombinant His-tagged LRRK2 protein fragment corresponding to amino acid
residues 841-960.The shuttling vector pCR8/GW/TOPO and the mammalian expression
GST-tagged vector pDEST27 were purchased from Invitrogen (Carlsbad, CA). Bovine
MBP and the synthetic peptides Kemptide (LRRASLG), caesin kinase 2 substrate
(RRRADDSD), MBP fragment 104-118 (GKGRGLSLSRFSWGA), and [Ser25]-PKC
fragment 19-31 (RFARKGSLRQKNV) were purchased from Sigma-Aldrich (St. Louis,
MO). The synthetic peptides MBP fragment 4-14 (KRPSQRSKYL), MBP fragment 94102 (APRTPGGRR), MARCKS-derived peptide (KKRFSFKKSFKL), and PKC-delta
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peptide

substrate

(RFAVRDMRQTVAVGVIKAVDKK)

were

purchased

from

Calbiochem/EMD Biosciences (Gibbstown, NJ). LRRKtide (RLGRDKYKTLRQIRQ)
was synthesized and purified on reverse phase HPLC by the W.M Keck Biotechnology
Resource Center at Yale University, New Haven, CT. The following kinase inhibitors
were purchased from Calbiochem/EMD Biosciences: IC261, 5,6-dichloro-1-beta-Dribofuranosylbenzimidazole (DRB), Gö6976, H89, K-252a, K-252b, kenpaullone, KN62, LY294002, ML-7, olomoucine, PD98059, Raf1 kinase inhibitor I, rapamycin,
roscovitine, SB203580, staurosporine, U0126, wortmannin, Y-27632.
Cell Culture
Human embryonic kidney 293T cells (293T) were cultured in Dulbecco's modified
medium (DMEM) high glucose (4.5gm/L) supplemented with 10 % fetal bovine serum
(FBS), 100U/ml penicillin, 100U/ml streptomycin, and 2mM L-glutamine.
LRRK2 Expression Constructs
The full-length human LRRK2 cDNA was amplified by PCR using Taq polymerase
AccuPrime SuperMix (Invitrogen) and cloned by topoisomerase reaction into the
shuttling vector pCR8/GW/TOPO. To generate the cDNA encoding the G2019S
mutation, the LRRK2 cDNA fragment spanning the AvrII and NcoI restriction sites in
LRRK2 was amplified by PCR and cloned by topoisomerase reaction into the vector
pCR4-TOPO (Invitrogen). The mutation corresponding to the G2019S amino acid
substitution was generated using the QuickChange® Site Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). A LRRK2 AvrII/NcoI cDNA fragment containing the LRRK2
“triple kinase-dead” (TKD) mutant (131) was amplified by PCR using a plasmid kindly
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provided by Dr. Mark Cookson and cloned in the vector pCR4-TOPO. In this TKD
mutant, the amino acid responsible for ATP binding (K1906A), the active site aspartate
(D1994A), and the Mg2+ binding site (D2017A) ware mutated. The AvrII/NcoI DNA
fragments containing either the G2019S or TKD mutant were reintroduced into fulllength LRRK2 by subcloning with these restriction enzymes. The sequence of the
plasmids was verified by DNA sequencing using primers that span the whole cDNA as a
service offered by the DNA Sequencing Facility of the University of Pennsylvania.
WT and mutants full-length LRRK2 cDNAs were introduced into the pDEST27 vector
by recombinase reaction using LR Clonase II enzyme (Invitrogen) to generate a plasmid
expressing N-terminal GST-tagged protein.
Western Blotting Analysis
Proteins

were

resolved

on

SDS-polyacrylamide

gels

by

SDS-PAGE

and

electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, Ca) in buffer containing 190 mM glycine, 25 mM Tris-base and 10 %
methanol. Membranes were blocked with a 5% powdered skimmed milk solution
dissolved in Tris buffered saline (50 mM Tris, pH 7.6, 150 mM NaCl), incubated with
primary antibody followed with an anti-goat antibody conjugated to horse radish
peroxidase,

developed

with

Western

Lightning

Chemiluminescence

Reagents

(PerkinElmer Life Sciences (Boston, MA) and exposed onto X-Omat Blue XB-1 films
(Kodak, Rochester, NY).
In-Vitro LRRK2 Kinase assays
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293T cells were transiently transfected with pDEST27/LRRK2 expression plasmid using
calcium phosphate precipitation method buffered with N, N-bis (2-hydroxyethyl)-2amino-ethanesulfonic acid (BES) (42). 48-72 hours after transfection, cells were washed
and harvested with PBS, and resuspended in lysis buffer (25nM Tris pH 7.4, 5nM EDTA,
10mM beta-glycerol phosphate, 1mM NaVO4, 1% Triton X-100, 0.5% glycerol with
protease inhibitor cocktail) at 4ºC. Cell debris were removed by sedimentation at
13,000xg for 15 min, and supernatants were precleared by incubation with sepharose
beads that were removed by sedimentation. Supernatants were incubated with
glutathione-sepharose beads (GE Healthcare) for 3 hrs at 4ºC. Beads were extensively
washed with lysis buffer (5 times) and wash buffer (25mM Hepes, pH. 7.4, 1mM DTT,
10 mM β-glycerophosphate)(5 times) and eluted with wash buffer with 20mM
glutathione. Kinase reactions were conducted at 25oC by incubating purified GSTLRRK2 in 25µL of kinase buffer (25mM Hepes, pH. 7.4, 1mM DTT, 10mM βglycerophosphate, 10mM MnCl2, 1µM ATP, 5µCi [γ-32P]ATP) with 0.04 mg/ml MBP or
0.04 mg/ml synthetic peptide. For autophosphorylation or phosphorylation of MBP,
reactions were stopped with the addition of sodium dodecyl sulfate (SDS) sample buffer
and heating to 100°C for 5 min. Samples were resolved onto 6% or 15% SDSpolyacrylamide gels, stained with Commassie R-250 staining solution (0.5% Coomassie
R-250, 25% isopropanol, 10% acetic acid), destained with 50% methanol/5% glycerol,
dried and exposed to a PhosphorImager plate (Molecular Dynamics, Piscataway, NJ), and
visualized using ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA). For
the analysis of the phosphorylation of peptides, peptides were applied to individual
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2.5cm-diameter disks of P-81 phosphocellulose filter paper (Schleicher & Schuell) that
were immediately immersed in 75mM phosphoric acid. After extensive wash with 75mM
phosphoric acid, P-81 filters were rinsed with acetone and allowed to air dry. Filters were
immersed in Cytoscint liquid scintillation cocktail (Fisher Scientific) and 32P radioactivity
on each filter was measured by liquid scintillation using an LS6500 counter (Beckman
Coulter).

RESULTS AND DISCUSSION
Generation and Characterization of Active Full-Length GST-LRRK2.
In order to readily generate substantial amounts of purified LRRK2, the full-length
enzyme was expressed in 293T cells as an N-terminal tagged GST protein that was
purified using glutathione-sepharose beads as described in “Materials and Methods” (Fig.
3-1A). Since the G2019S mutation is the most common alteration causal of PD and
several studies have demonstrated increased kinase activity due to this mutation, the
enzyme with this mutation was also produced. To verify the specificity of each enzyme,
the “TKD” kinase dead version of this protein (131) also was assayed. The in-vitro
kinase activity of recombinant WT and G2019S GST-LRRK2 was investigated by autophosphorylation and phosphorylation of the generic kinase substrate MBP (Fig. 3-1A).
The G2019S mutation resulted in a 3-5 fold increase in levels of autophosphorylation as
well as MBP phosphorylation. The TKD protein demonstrated a paucity of kinase
activity. To further confirm the specificity of this activity, it was assessed with the
synthetic peptide LRRKtide, which contains residue T688 in moesin that was previously
identified as a good substrate for LRRK2 (160). Recombinant WT GST-LRRK2 readily
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phosphorylated LRRKtide, while the dead mutant showed no activity. In contrast, the
activity for the G2019S mutant was ~10 times higher than for WT in this assay (Fig 31B), suggesting that the effects of the G2019S mutation may be more pronounced than
previously believed. The reason(s) for the greater increase in kinase activity by the
G2019S mutation using LRRKtide in this system are currently under investigation.
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Figure

3-1.

Characterization

of

recombinant GST-LRRK2 activity. (A)
Western blot analysis with anti-GST or
anti-LRRK2
glutathione

(1182)

antibody

affinity

showing

chromatography

purified WT, G2019S and TKD GSTLRRK2 compared to mock transfection.
Autoradiography showing that WT and
G2019S

GST-LRRK2

autophosphorylation

and

undergo
that

they

phosphorylate MBP, while the TKD mutant
is deficient in activity, similar to mock
transfection.

(B-D)

Substrate

peptide

analysis showing that WT and G2019S
GST-LRRK2

specifically

phosphorylate

LRRKtide, but not a spectrum of other
kinase peptide substrates.

To further characterize the in-vitro kinase activity of LRRK2, and screen for other motifs
that this enzyme may recognize, the ability of GST-LRRK2 to phosphorylate
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characterized synthetic peptides with known kinase recognition motifs was analyzed.
Some of the peptides studied were based on the ability of LRRK2 to phosphorylate MBP
as well as the findings from the inhibitor studies (see below). GST-LRRK2 was assayed
for the ability to phosphorylate PKC substrates (MBP fragment 104-118, [Ser25]-PKC
fragment 19-31, MBP fragment 4-14, MARCKS PSD-Derived peptide), ERK1/2
substrate (MBP fragment 94-102), PKA substrate (Kemptide), and casein kinase II
specific peptide (Figs. 3-1C and D). Compared to reactions using LRRKtide, these
peptides demonstrated less than 5% of the level of phosphorylation indicating that they
are not substrates for LRRK2 (Fig. 3-1C). Similarly, none of these peptides were
substrates for G2019S GST-LRRK2 (Fig. 3-1D).
Recombinant GST-LRRK2 was used to Screen a Range of Defined Kinase
Inhibitors.
Compounds (listed in “Material and Methods”) specific for different families of kinases
including protein kinase A, protein kinase C, mitogen-activated protein kinase, mitogenactivated protein kinase kinase, casein kinase I/II, Ca2+/calmodulin-dependent kinase II,
glycogen synthase kinase-3, Rho kinase, Raf kinase, myosin light chain kinase, cyclindependent kinases and mixed lineage kinases were assayed using a 1-10uM range. The
majority of compounds had no significant affect on kinase activity (data not shown);
however five inhibitors that abolished kinase activity were identified, and were further
characterized (Fig 3-2). Two of these inhibitors inhibited LRRK2 in the high nM range:
Raf-1 kinase inhibitor I (IC50 ~500nM) (Fig 2D) and Gö6976 (IC50 ~250nM) (Fig 32A). Three other inhibitors were much more potent, inhibiting LRRK2 in the low nM
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range: staurosporine (IC50 ~1nM) (Fig 2E), K252a (IC50 ~25nM) (Fig 3-2B), and
K252b (IC50 ~50nM) (Fig 3-2C). Similarly, all these inhibitors demonstrated the ability
to inhibit G2019S LRRK2 (Fig 3-2F).

Figure 3-2. Analysis of GST-LRRK2 kinase activity in the presence of various inhibitors. (A) Gö6976,
(B) K-252a, (C) K252-b, (D) Raf-1 kinase inhibitor 1 and (E) Staurosporine are shown to be potent
inhibitors of WT GST-LRRK2 using a range of concentration that was used to approximate the IC50. (F)
G2019S GST-LRRK2 was also efficiently inhibited by these kinase inhibitors. The values correspond to
the phosphorylation of LRRKtide in the presence of each inhibitor relative to reactions without inhibitors
expressed as percent activity. (n=3, Error bars indicate standard error)

The four most potent inhibitors of LRRK2 identified here (Gö6976, K252a, K252b and
staurosporine) all have a basic indolocarbazole structure: a symmetric fusion of
alternating three benzene and two pyrrole rings with a pyrrolidione ring fused to the
central benzene structure (135, 274). These molecules are competitive inhibitors
interacting with the ATP binding site of kinases (86, 169, 171). Although staurosporine
is a potent kinase inhibitor, it is not very specific (86, 169).
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K252a and K252b were

identified from the culture broth of the Nocardiopsis bacterium, and although they were
initially shown to inhibit PKC (171), they also have been shown to inhibit several other
kinases (147, 339). Gö6976 was developed as a specific inhibitor of some PKC isozymes
(223), but more recently it was shown to also inhibit several other kinases (15). The
identification of kinases inhibitors that are completely specific has been a challenge, but
once a specific basis structure has been identified several approaches can be used to
rationally modify kinase inhibitors to make them more selective ligands (35, 57, 193,
339).
The identification of potent LRRK2 kinase inhibitors will serve as useful tools for in vivo
findings where LRRK2 is overexpressed to characterize its biological function. More
importantly, these compounds can be used as the starting points to generate more
selective inhibitors that could have therapeutic application given that elevated LRRK2
activity is a likely cause of pathogenesis in patients with LRRK2 mutations.

74

CHATPER FOUR
THE PATHOGENIC G2019S MUTATION DISRUPTS SENSITIVITY
OF LEUCINE-RICH REPEAT KINASE 2 TO MANGANESE KINASE
INHIBITION

Data from this chapter was published in:
Covy JP, Giasson BI (2010). The pathogenic G2019S mutation disrupts sensitivity of
leucine-rich repeat kinase 2 to manganese kinase inhibition. J Neurochem. (In Press)
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ABSTRACT
Mutations in leucine-repeat rich kinase-2 (LRRK2) are the most common cause of lateonset Parkinson disease. Previously, we showed that the G2019S pathogenic mutation
can cause a dramatic increase (~10 fold) in kinase activity, far above other published
studies. A notable experimental difference was the use of Mn-ATP as a substrate.
Therefore, the effects of metal cation-ATP cofactors on LRRK2 kinase activity were
investigated. It is shown, using several divalent metal cations, that only Mg2+ or Mn2+ can
support LRRK2 kinase activity. However, for wild-type, I2020T and R1441C LRRK2,
Mn2+ was significantly less effective at supporting kinase activity. In sharp contrast, both
Mn2+and Mg2+ were effective at supporting the activity of G2019S LRRK2. These
divergent effects associated with divalent cation usage and the G2019S mutation were
predominantly due to differences in catalytic rates. However, LRRK2 was shown to have
much lower (~40 fold) ATP Km for Mn-ATP compared to Mg-ATP. Consequently, substoichiometric concentrations of Mn2+ can act to inhibit the kinase activity of wild-type,
but not G2019S LRRK2 in the presence of Mg2+. From these findings, a new model is
proposed for a possible function of LRRK2 and the consequence of the G2019S LRRK2
pathogenic mutation.
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INTRODUCTION
Parkinson disease is the second most prevalent neurodegenerative disease in the
developing world, and is believed to result from complex genetic and environmental
factors. It is characterized clinically by resting tremor, bradykinesia, postural instability,
and muscle rigidity (152, 292). Although primarily viewed as an idiopathic disease, a
number of gene defects have been established to either cause or increase the risk of PD
[reviewed in (23, 28, 92, 143, 275, 318)]. More specifically, autosomal dominant
missense mutations in the gene for LRRK2 (PARK8) are the most common known cause
of PD (110, 250, 355). At least 5 LRRK2 missense mutations are considered definitely
pathogenic, but many other amino acid substitutions within this protein have been linked
to PD (see Fig. 1A) (26, 110, 224, 250, 314, 355). The most prevalent mutation, G2019S,
is reportedly responsible for 0.6-1.6% of sporadic PD (69, 111, 166) and 2-8% of familial
PD cases (69, 73, 145, 166, 245, 251). In certain ethnicities, such as North African Arabs
and Ashkenazi Jews, the G2019S mutation is even a greater factor contributing to PD
(22-41% of individuals with disease) (198, 199, 248).
LRRK2 is a widely-expressed 2527 amino acid protein with several discrete domains
(Fig. 4-1A) (250, 343, 355). Containing a Ras-of-complex (ROC)/GTPase domain
followed by a C-terminal of RAS (COR) domain, it is a member of the ROCO protein
family (see Fig. 4-1A). The LRRK2 kinase domain displays highest sequence homology
to the mixed-linage kinase subfamily of mitogen-activated protein kinase kinase kinases,
so named due to kinase sub-domain structures resembling both protein Y- and S/Tkinases (218, 342, 343). To date it has been shown that LRRK2 can function as a S/T77

kinase that can undergo autophosphorylation (7, 53, 134, 160, 213, 296, 342, 343);
although its ability to function as a Y-kinase has not been rigorously investigated. Some
modeling studies have suggested that LRRK2 may be a dual specificity kinase,
phosphorylating both S/T and Y residues (218, 343), but so far it has been shown to
function predominantly as a S/T-kinase (7, 343) and only weak activity towards the Ykinase substrate poly(E)tyrosine was reported (342).

Furthermore, the biological

functions and regulation of LRRK2, and the effects of disease-causing mutations therein
are still ill-defined(130). For example, the R1441C mutation was demonstrated to
increase kinase activity in some studies(342, 343), but others have reported no significant
change (7, 118, 160). The I2020T mutation was documented to either modestly increase
(117, 118), show no change (7) or decrease kinase activity (160). Most studies of the
G2019S mutation demonstrated increased kinase activity, although modest (2-3 fold) (7,
118, 131, 160, 342, 343). Recently, we have shown that in one experimental paradigm,
the G2019S LRRK2 mutant can demonstrate 10-fold greater kinase activity than wildtype (WT) LRRK2 (53). One notable difference is that we used Mn2+ as an ATP cofactor,
while most other published studies have used Mg2+. Therefore, in this study we assessed
the relative kinetic effects of Mg2+ versus Mn2+ on the catalytic properties of WT LRRK2
and some disease-causing mutants thereof.
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Figure 4-1. Characterization of recombinant LRRK2 kinase activity. (A) Schematic of LRRK2
showing the major domains [ankyrin-like (ANK), Leucine-rich repeat (LRR), Ras-in-complex (ROC), Cterminal of RAS (COR)] and the position of the mutations that are considered definitely pathogenic. (B)
Western blot with anti-GST antibody showing equal amounts of glutathione affinity-purified recombinant
WT and mutant (G2019S, I2020T and R1441C) GST-LRRK2 full-length proteins. (C) Relative kinase
activity of WT, R1441C, G2019S, and I2020T LRRK2 using 200µM ATP, 400µM LRRKtide and several
individual divalent cations (Mg2+, Mn2+, Cd2+, Ca2+, Ni2+, Zn2+) at 5mM. The data was standardized so that
the phosphorylation reaction of LRRKtide with Mg2+ for each LRRK2 variant was normalized to 100%.
(D) Comparative assessment of the ability of WT and G2019S LRRK2 to phosphorylate LRRKtide,
LRRKtide-TA or LRRKtide-YF (300µM each) in the presence of 200µM ATP and either 5mM Mg2+ or
Mn2+. (E) Assay demonstrating that the time-course of LRRK2 kinase activity was linear over 120 min
using 200µM ATP, 400µM LRRKtide and either 5mM Mg2+ or Mn2+. For each LRRK2 variant, the activity
was standardized as 100% for kinase reactions in 5mM Mg2+ at 60 minutes. The error bars represent
standard error of the mean.

MATERIALS AND METHODS
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Materials
Goat anti-GST polyclonal antibody was purchased from Amersham Biosciences
(Piscataway, NJ). The shuttling vector pCR8/GW/TOPO and the mammalian expression
GST-tagged vector pDEST27 were purchased from Invitrogen (Carlsbad, CA).
LRRKtide (RLGRDKYKTLRQIRQ), LRRKtide-TA (RLGRDKYKALRQIRQ) that is
deficient in S/T residues, LRRKtide-YF (RLGRDKFKTLRQIRQ) that is deficient in Y
residues, and Nictide (RLGWWRFYTLRRARQGNTKQR) were synthesized and
purified on reverse phase HPLC by GenScript USA Inc. (Piscataway, NJ). The synthetic
peptides MBP fragment 104-118 (GKGRGLSLSRFSWGA), Kemptide (LRRASLG), and
caesin kinase 2 substrate (RRRADDSD) were purchased from Sigma-Aldrich (St. Louis,
MO). The synthetic peptides MBP fragment 4-14 (KRPSQRSKYL), MBP fragment 94102 (APRTPGGRR), MARCKS PSD-derived peptide (KKRFSFKKSFKL), and PKCδ
peptide

substrate

(RFAVRDMRQTVAVGVIKAVDKK)

were

obtained

from

Calbiochem/EMD Biosciences (Gibbstown, NJ). Kinase inhibitors JAK3 VI, K252-A,
PKR, ROCK-IV, and staurosporine were purchased from Calbiochem/EMD Biosciences,
and sunitinib was purchased from Sigma-Aldrich.
Cell Culture
Human embryonic kidney 293T cells were cultured in Dulbecco's modified medium with
high glucose (4.5gm/L) supplemented with 10% fetal bovine serum, 100U/ml penicillin,
100U/ml streptomycin, and 2mM L-glutamine.
LRRK2 Expression Constructs
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The full-length human LRRK2 cDNA was amplified by PCR using Taq polymerase
AccuPrime SuperMix (Invitrogen) and cloned by topoisomerase reaction into the
shuttling vector pCR8/GW/TOPO. To generate the cDNAs encoding the G2019S or
I2020T mutations, the LRRK2 cDNA fragment spanning the AvrII and NcoI restriction
sites in LRRK2 was amplified by PCR and cloned by topoisomerase reaction into the
vector pCR4-TOPO (Invitrogen). To generate the cDNA encoding the R1441C mutation,
the LRRK2 cDNA fragment spanning the NdeI and SpeI restriction sites in LRRK2 was
amplified by PCR and cloned by topoisomerase reaction into the vector pCR4-TOPO
(Invitrogen). The mutations corresponding to the R1441C, G2019S or I2020T amino acid
substitutions, respectively, were generated using the QuickChange® Site Directed
Mutagenesis Kit (Stratagene, La Jolla, CA). The AvrII/NcoI DNA fragments containing
either the G2019S or I2020T mutants or the NdeI/SpeI DNA fragments containing the
R1441C mutation were reintroduced into full-length LRRK2 by subcloning with these
restriction enzymes. The sequence of the plasmids was verified by DNA sequencing
using primers that span the whole cDNA as a service offered by the DNA Sequencing
Facility of the University of Pennsylvania. WT and mutant full-length LRRK2 cDNAs
were introduced into the pDEST27 vector by recombinase reaction using LR Clonase II
enzyme (Invitrogen) to generate a plasmid expressing N-terminal GST-tagged protein.
Western Blotting Analysis
Proteins

were

resolved

on

SDS-polyacrylamide

gels

by

SDS-PAGE

and

electrophoretically transferred onto nitrocellulose membranes (Bio-Rad Laboratories,
Hercules, Ca) in buffer containing 190mM glycine, 25mM Tris-base and 10% methanol.
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Membranes were blocked with a 5% powdered skimmed milk solution dissolved in Tris
buffered saline (50mM Tris, pH 7.6, 150mM NaCl), incubated with anti-GST antibody
followed with an anti-goat antibody conjugated to horse radish peroxidase, developed
with Western Lightning Chemiluminescence Reagents (PerkinElmer Life Sciences
(Boston, MA) and exposed onto X-Omat Blue XB-1 films (Kodak, Rochester, NY).
In-Vitro LRRK2 Kinase Assays
293T cells were transiently transfected with pDEST27/LRRK2 expression plasmid using
calcium phosphate precipitation method buffered with N, N-bis (2-hydroxyethyl)-2amino-ethanesulfonic acid (BES) (42). 48-72 hours after transfection, cells were washed
and harvested with PBS, and resuspended in lysis buffer (25mM Tris pH 7.4, 150mM
NaCl, 5mM EDTA, 10mM beta-glycerol phosphate, 1mM NaVO4, 1 % Triton X-100,
0.5% glycerol with protease inhibitor cocktail) at 4oC. Cell debris were removed by
sedimentation at 13,000xg for 15 minutes, and supernatants were precleared by
incubation with sepharose beads that were removed by sedimentation. Supernatants were
incubated with glutathione-sepharose beads (GE Healthcare) for 3 hours at 4oC. Beads
were extensively washed with lysis buffer (5 times) and wash buffer (25mM Hepes, pH.
7.4, 1mM DTT, 10mM β-glycerophosphate) (5 times) and eluted with wash buffer with
20mM glutathione. The kinase reactions were conducted at 25oC by incubating purified
GST-LRRK2 in 25µL of kinase buffer (25mM Hepes, pH. 7.4, 10mM βglycerophosphate), with the added specified divalent cation, and varying [γ-32P]ATP (4
Ci/mmoles) (1µM to 800µM) and LRRKtide peptide (1µM to 1200µM) concentrations as
specified for each experiment. All reactions were conducted for 60 minutes at 25oC,
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except for the time course experiments that were conducted for the indicated times.
Reactions were applied to individual 2.5cm-diameter disks of P-81 phosphocellulose
filter paper (Schleicher & Schuell) that were immediately immersed in 75mM phosphoric
acid. After extensive wash with 75mM phosphoric acid, P-81 filters were rinsed with
acetone and allowed to air dry. Filters were immersed in Cytoscint liquid scintillation
cocktail (Fisher Scientific) and

32

P radioactivity on each filter was measured by liquid

scintillation using an LS6500 counter (Beckman Coulter). A unit of LRRK2 activity was
defined as the amount of enzyme that catalyzed the incorporation of 1pmol of

32

P into

LRRKtide. Km and Vmax parameters were calculated using Graph-Pad Prism v5.01.
For autophosphorylation of LRRK2, reactions were stopped with the addition of SDS
sample buffer and heating to 100°C for 5 min. Samples were resolved onto 6% SDSpolyacrylamide gels, dehydrated in a 50% Methanol, 10% glycerol, 10% acetic acid
solution, dried and exposed to a PhosphorImager plate (Molecular Dynamics,
Piscataway, NJ), and visualized using ImageQuant software (Molecular Dynamics, Inc.,
Sunnyvale, CA).

RESULTS
We recently generated a novel system to purify substantial amounts of active
recombinant full-length LRRK2 expressed in 293T mammalian cells

(53)

. In this system,

LRRK2 is expressed as an N-terminal tagged GST protein that is purified using
glutathione-sepharose beads as described in “Materials and Methods”.

The kinase

activity of this enzyme was previously characterized for specificity using a kinase dead
version as well as kinase inhibitors in the presence of Mn2+. The specificity of this
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activity was further confirmed using a series of previously published and characterized
LRRK2 kinase inhibitors (7, 244, 273) in the presence of Mg2+ (Fig. 4-2). For the studies
described here, WT and 3 pathogenic mutants of LRRK2 (R1441C, G2019S, and
I2020T) were purified to equivalent levels (Fig. 4-1B).

The kinase reactions in the

present studies were conducted using the synthetic peptide LRRKtide that spans residue
T558 of moesin, which was previously identified as a robust in vitro substrate for LRRK2
(7, 34, 53, 160).

Figure 4-2. Analysis of WT and G2019S LRRK2 kinase activity in the presence of various inhibitors.
Kinase reactions were conducted using 400µM LRRKtide, 100µM ATP, and 5 mM Mg2+. JAK3 VI, K252A, PKR, ROCK-IV, stuarosporine, and sunitinib are shown to be potent inhibitors of WT and G2019S
LRRK2 at a concentration of 1µM. Values correspond to the phosphorylation of LRRKtide in the presence
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of each inhibitor relative to reactions without inhibitor expressed as percent activity. The error bars
represent standard error of the mean.

Protein kinases require the formation of an ATP-divalent metal complex for the
phosphoryl transfer of the γ-phosphate of ATP to a protein substrate (178). Typically,
Mg2+ serves as the essential metal ion for catalysis, however Mn2+ and other divalent
cations may support nucleotide binding and subsequent use as a cofactor for phosphoryl
transfer (52, 84, 180, 306, 324). Several divalent metal cations were tested to assess their
ability to act as an ATP cofactor for WT and pathogenic variants of LRRK2. This
analysis was conducted for pathological mutations within the active site (G2019S and
I2020T) as well as a pathological mutation distinct from this site (R1441C).

Of the

divalent metal cations assessed, Mg2+ demonstrated the greatest ability to support LRRK2
kinase activity under the reaction conditions used here (200 µM ATP, 400 µM
LRRKtide) (Fig. 1C). Mn2+ also demonstrated a modest ability to promote LRRK2 kinase
activity of WT, R1441C and I2020T LRRK2, however this property was greatly
enhanced for the G2019S LRRK2 mutant. The other divalent cations tested were not able
to support LRRK2 kinase activity.
It is well known that many Y-kinases prefer Mn2+ as an ATP cofactor (52, 84, 155, 180,
306), and for some dual specificity kinases, the presence of Mn2+ versus Mg2+ can cause a
switch in preferential activity from a protein S/T-kinase to a protein Y-kinase (154, 350) .
Therefore, it is possible that Mn2+ may support the activity of LRRK2 as a Y-kinase since
LRRKtide (RLGRDKYKTLRQIRQ) contains both a T and a Y residue. To further
investigate the type of kinase activities associated with the use of Mg2+ or Mn2+, kinase
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reactions for WT, R1441C, G2019S, and I2020T LRRK2 were performed in the presence
of 5 mM Mg2+ or Mn2+ and LRRKtide, LRRKtide deficient in S/T residues (LRRKtideTA; RLGRDKYKALRQIRQ) or LRRKtide that is deficient in Y residues (LRRKtideYF; RLGRDKFKTLRQIRQ). Results showed that only LRRKtide with a T residue
served as a substrate for LRRK2 in the presence of Mg2+ or Mn2+ (Fig. 4-1D). To further
confirm that the persistence of kinetic activity of the G2019S mutant in the presence of
Mn2+ is not a result of altered substrate specificity, a number of other characterized
synthetic peptides with known kinase recognition motifs, including the engineered
LRRK2 substrate Nictide (244), were analyzed in the presence of Mg2+ or Mn2+, and no
differences in substrate recognition were observed (Fig. 4-3).
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Figure 4-3. Substrate specificity of WT and G2019S LRRK2. WT and G2019S LRRK2 was assayed for
the ability to phosphorylate PKC substrates (MARCKS PSD-derived peptide, MBP fragment 4-14, MBP
fragment 104–118, PKCδ peptide substrate), ERK1/2 substrate (MBP fragment 94–102), PKA substrate
(Kemptide), casein kinase II specific peptide, and known LRRK2 substrates (LRRKtide and Nictide) in the
presence of either 5mM Mg2+ or Mn2+. ATP concentration was at 200µM, and substrates were at 300µM
(except for Nictide which was at 30µM). The error bars represent standard error of the mean.

Time course analysis of the kinase activity for WT, R1441C, G2019S, and I2020T
LRRK2 in the presence of Mg2+ or Mn2+ was performed to determine the consistent
progress of the phosphoryl transfer over time. Results showed that the kinase reaction
was linear over the course of two hours, allowing extrapolation of initial velocity and
confirming that differences in kinetic activity were not due to changes in kinase stability
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(Fig. 4-1E). In addition, similar to our initial screen of divalent cations, WT, R1441C,
G2019S, and I2020T LRRK2 kinase activity was much greater in the presence of Mg2+
compared to Mn2+ for all enzymes except the G2019S mutant.
To further investigate the effects of Mg2+ and Mn2+ on LRRK2 kinase activity, the ability
and extent of each ion to support kinase activity was assessed by varying their
concentrations. For all variants of LRRK2 assayed against LRRKtide, increasing the
concentration of Mg2+ resulted in increased kinase activity with maximum activity at
5mM. Mn2+ also supported the kinase activity of LRRK2, but maximal activity was
observed at ~ 0.5mM and all variants demonstrated a similar relative decrease in activity
at higher concentrations with ~ 2-fold lower activity at 5mM Mn2+ compared to 0.5mM
Mn2+ (Fig. 4-4). R1441C and I2020T mutants demonstrated Mn2+ concentration activity
profiles that were similar to WT LRRK2, but G2019S LRRK2 revealed dramatically
greater activity than the other LRRK2 variants in the presence of Mn2+ and this was
especially striking in the presence of Mn2+ below or near sub-stoichiometric
concentrations of ATP.
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Figure 4-4. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of WT, R1441C,
G2019S, and I2020T LRRK2 on LRRKtide phosphorylation. Kinase reactions for (A) WT, (B)
R1441C, (C) G2019S and (D) I2020T LRRK2 were conducted using 200µM ATP, 400µM LRRKtide and
varying concentrations of Mg2+ or Mn2+ between 0.1mM and 10mM. The error bars represent standard
error of the mean.

These effects were replicated using the synthetic substrate Nictide (Fig. 4-5). Again,
Mn2+ is capable of driving kinase activity, although not to the extent of Mg2+ for WT,
R1441C, and I2020T LRRK2. For G2019S LRRK2, Mn2+ demonstrated the ability to
drive much greater kinase activity than for the other LRRK2 variants, and in fact,
G2019S LRRK2 showed greater kinase activity in the presence of Mn2+ compared to
Mg2+ (Fig. 4-5). Although the effects of Mg2+ and Mn2+ on WT, R1441C, G2019S and
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I2020T LRRK2 kinase activity using either LRRKtide or Nictide are consistent, there are
some relative differences and more detailed kinetic studies of the difference between
LRRKtide and Nictide are under investigation.

Figure 4-5. Concentration dependent affects of Mg2+ and Mn2+on the kinase activity of WT, R1441C,
G2019S, and I2020T LRRK2 on Nictide phosphorylation. Kinase reactions for (A) WT, (B) R1441C,
(C) G2019S and (D) I2020T LRRK2 were conducted using 200µM ATP, 30µM Nictide and varying
concentrations of Mg2+ or Mn2+ between 0.1mM and 10mM. The error bars represent standard error of the
mean.

Similar results for divalent cation preference were observed for autophosphorylation of
LRRK2. Increasing concentrations of Mg2+ drove robust autophosphorylation of both
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WT and G2019S LRRK2, and these levels were greatly reduced in the presence of Mn2+
for WT, but not G2019S (Fig. 4-6A).

Interestingly, 0.1mM Mn2+ induced higher

autophosphorylation activity in both WT and G2019S LRRK2 compared to Mg2. This
selectivity may reflect higher affinity for ATP-Mn (see below), but direct affects of
divalent cations on LRRK2 autophosphorylation cannot be excluded and this will require
further detailed analyses.

Nevertheless, consistent with LRRKtide, WT LRRK2

exhibited lower autophosphorylation activity in 5mM Mn2+ versus 5mM Mg2+, while
G2019S LRRK2 displayed similar autophosphorylation in the presence of either 5mM
Mn2+or Mg2+ (Fig. 4-6B).
Figure 4-6. Concentration dependent affects of
Mg2+ and Mn2+ on the autophosphorylation
activity of WT and G2019S LRRK2.

(A)

Kinase reactions for WT and G2019S were
conducted using 100 uM ATP and with varying
concentrations of divalent cation between 0.1
mM and 10 mM. Autoradiography shows the
effects of increased concentration of Mg2+ or
Mn2+ autophosphorylation activity.

(B) The

relative activity of WT and G2019S LRRK2
when using either Mg2+ or Mn2+ as cofactor at 5
mM. The error bars represent standard error of
the mean.
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To investigate the nature of the differences in the kinetics properties affected by Mg2+
versus Mn2+ and the provocative effects of the G2019S LRRK2 pathogenic mutation, the
Michaelis-Menton parameters were determined for WT, R1441C, I2020T, and G2019S
LRRK2 using LRRKtide as a substrate. To ensure that the ATP-cation complex was at
saturating levels, 5mM Mg2+ or Mn2+ was used to remain at a concentration several fold
above the highest concentration of ATP.

Furthermore, results showed at this

concentration of Mg2+, maximal LRRK2 activity is obtained. Kinetic analyses for the Km
of LRRKtide, while keeping the ATP concentration constant at 200µM, revealed values
consistent with previous reports utilizing Mg2+ and N-terminally truncated versions
(LRRK21326-2527 or LRRK2970-2527) of LRRK2 (7, 160, 244). The affinity for LRRKtide
was not dramatically affected by the use of Mg2+ and Mn2+, or by mutations in LRRK2;
although some subtle changes were observed (Fig. 4-7). The apparent Vmax’s measured
under these conditions revealed that WT, I2020T and R1441C LRRK2 had much greater
relative catalytic rates (~10 fold) in the present of Mg2+ versus Mn2+. In regards to each
respective cation, the R1441C and I2020T mutants resulted in only small changes in
catalytic rate compared to WT, while the apparent Vmax for G2019S in the presence of
Mg2+ was ~2.5-fold greater than WT LRRK2. However the most dramatic effect was the
relative maintenance of catalytic activity of G2019S LRRK2 in the presence of Mn2+
relative to Mg2+. This effect was unique to the G2019S mutation. In fact, for G2019S
LRRK2, the Vmax in the presence of Mn2+ compared to Mg2+ was only ~ 1.5 fold lower,
in contrast to the ~9 fold lower activity for WT, R1441C, and I2020T LRRK2.
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Km
Wildtype
R1441C
G2019S
I2020T

Mg
208.9 +/208.6 +/243.8 +/251.7 +/-

11.50
17.30
19.64
37.80

Vmax
Mn
242.6 +/300.5 +/235.8 +/255.5 +/-

Mg
14.74
30.55
13.09
35.91

2.57
3.63
6.80
3.31

+/- 0.046
+/- 0.102
+/- 0.243
+/- 0.146

Mn
0.304 +/0.286 +/5.222 +/0.282 +/-

0.005
0.009
0.084
0.012

Figure 4-7. Kinetic characteristics of WT and LRRK2 mutations while varying the concentration of
LRRKtide as a substrate. (Top) Assessment of the kinetic features of (A) WT, (B) R1441C, (C) G2019S
and (D) I2020T recombinant LRRK2 with ATP at 200µM with either 5mM Mg2+ or 5mM Mn2+. The
concentration of LRRKtide was varied as indicated on the x-axis. The error bars represent standard error of
the mean. (Bottom) The relative apparent Vmax (U/min) and Km (mM) for. The errors represent standard
deviations.
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The determination of the apparent Km of ATP while keeping LRRKtide constant at
400µM revealed that WT LRRK2 and LRRK2 mutants have a significantly lower ATP
Km in the presence of Mn2+ compared to Mg2+ (Fig. 4-8). This suggests a greater affinity
for Mn-ATP than Mg-ATP. ATP Km for WT and R1441C had similar properties, while
I2020T LRRK2 had a relative lower ATP Km in the presence of either Mg2+ or Mn2+,
respectively. Conversely, G2019S LRRK2 demonstrated relatively higher ATP Km in the
presence of either Mg2+ or Mn2+, respectively, compared to WT LRRK2. Again, the
analyses to assess Vmax values showed that WT LRRK2 demonstrated a greater catalytic
rate in the presence Mg2+ versus Mn2+, however, the most striking finding was the much
higher Vmax for G2019S LRRK2 in the presence of Mn2+ compared to WT and other
mutants of LRRK2.
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Km

Vmax

Mg

Mn

Mg

Mn

Wildtype

54.53

+/-

4.73

1.40

+/-

0.173

2.08

+/-

0.044

0.189

+/-

0.003

R1441C

62.97

+/-

4.02

2.61

+/-

0.472

3.06

+/-

0.049

0.238

+/-

0.006

G2019S

74.08

+/-

7.73

3.93

+/-

0.436

4.68

+/-

0.126

3.315

+/-

0.057

I2020T

18.13

+/-

2.63

0.95

+/-

0.153

2.67

+/-

0.078

0.179

+/-

0.004

Figure 4-8. Kinetic characteristics of WT and LRRK2 mutations while varying the concentration of
ATP as a substrate. (Top) Assessment of the kinetic features of (A) WT, (B) R1441C, (C) G2019S and
(D) I2020T recombinant LRRK2 at 400µM LRRKtide with either 5mM Mg2+ or 5mM Mn2+. The
concentration of ATP was varied as indicated on the x-axis. The error bars represent standard error of the
mean. (Bottom) The relative apparent Vmax (U/min) and Km (mM) for. The errors represent standard
deviations.
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Since under physiological conditions, Mn2+ exists at sub-stoichiometric concentrations
relative to Mg2+, we compared the relative effects of varying sub-stoichiometric
concentrations of Mn2+ in the presence of a fixed concentration of Mg2+. For these
experiments, Mg2+ was maintained at 5mM while the concentration of Mn2+ was varied
between 0-5mM. Increasing the concentration of Mn2+ resulted in reduced kinase activity
for WT, R1441C and I2020T LRRK2 (Fig. 4-9A,B,D), consistent with a greater affinity
for Mn-ATP versus Mg-ATP paired with a reduction in catalytic activity when utilizing
Mn-ATP. In sharp contrast, increases in the concentration of Mn2+ between 0.1-1mM
increased the kinase activity of G2019S LRRK2, while only modestly reducing kinase
activity at 5mM Mn2+ (Fig. 4-9C). Given that G2019S LRRK2 levels of kinase activity
in the presence of Mn2+ reaches a maximum at ~1mM and that this activity is similar to
G2019S LRRK2 in the presence of 5mM Mg2+ (Fig. 4-4C), but that 5mM Mg2+ in the
presence of 0.1 or 0.5mM Mn2+ results in higher activity, it is possible that Mn2+ may
additionally modulate kinase activity by acting at a second site. Overall, these results are
consistent with those reported recently (212) and show that at millimolar concentrations
of Mg2+, micromolar concentrations of Mn2+ decrease the levels of LRRK2 kinase
activity, while the G2019S mutation causes a loss of this negative regulation, if not
reversing the effect and increasing activity.
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Figure 4-9. Analysis of effects of sub-stoichiometric concentrations of Mn2+ on WT and mutant
LRRK2 kinase activity driven by Mg2+. The activity of (A) WT, (B) R1441C, (C) G2019S and (D)
I2020T recombinant LRRK2 was assessed in the presence of 200µM ATP, 400µM LRRKtide and 5mM
Mg2+ with concentrations of Mn2+ varying from 0-5mM. As a reference, reactions with only 5mM Mn2+ are
also shown. For each LRRK2 variant, the activity was standardized as 100 % activity for kinase reactions
with only 5mM Mg2+. The error bars represent standard error of the mean.

DISCUSSION
In stark contrast to several other published findings (7, 118, 131, 160, 342, 343), we
recently demonstrated that the G2019S mutation in LRRK2 could result in a much
greater kinase activity relative to WT LRRK2 (53). A notable difference in our study was
the use of Mn2+ as an ATP cofactor compared to the use of Mg2+ in other studies. This led
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us to investigate the ability of divalent metal cations to support the kinase activity of WT
and several pathogenic mutants of LRRK2. It was shown that only Mg2+ or Mn2+ could be
used as ATP cofactors to support the kinase activity of LRRK2, and for WT, I2020T and
R1441C LRRK2, Mg2+ was a much better cofactor at promoting kinase activity.
Remarkably, both Mn2+and Mg2+ were effective at promoting the activity of G2019S
LRRK2. Using LRRKtide peptides deficient in either T or Y resides, it was shown that
WT and mutants of LRRK2 appear to be exclusively S/T-protein kinases, and Mn2+ does
not change this specificity. Furthermore, no changes in specificity were observed for a
number of known generic kinase substrates for WT or G2019S LRRK2 when utilizing
Mn2+ or Mg2+.

Interestingly, LRRK2 demonstrated greater activity towards the

LRRKtide-YF peptide compared to LRRKtide, however, this is consistent with a
previous study mapping the preferred consensus motif of LRRK2 substrates where it has
been shown that for the P-2 position, an F is favored over a Y residue (244).
Assessment of Michaelis-Menton parameters showed that the use of Mn2+ versus Mg2+
did not dramatically affect LRRKtide Km. Consistent with previous reports using Nterminally truncated versions of LRRK2 (7, 273), ATP Km for G2019S LRRK2 was
higher compared to WT LRRK2, while that of I2020T LRRK2 was lower in the presence
of Mg2+. WT and all mutants of LRRK2 demonstrated significantly lower ATP Km for
Mn-ATP compared to Mg-ATP, and similar findings have been attributed predominantly
to a high affinity for Mn-ATP (212). WT, R1441C and I2020T LRRK2 showed slower
catalytic rates in the presence of Mn2+ compared to Mg2+. A dramatically higher Vmax for
G2019S in the presence of Mn2+ compared to WT LRRK2 is the predominant reason for
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the ~10 fold greater level of kinase activity for G2019S LRRK2 versus WT LRRK2 that
we previously reported (53). Consistent with these data, similar findings were observed in
a recent study using a truncated version (LRRK2970-2527) of LRRK2 expressed and
purified from baculovirus-infected insect cells (212). However, the differences in ATP
Km for the different LRRK2 variants also indicate that relative kinase activity can be
affected depending on the concentration of ATP used in the reactions, especially around
or below the Km. In the presence of Mg2+, the relative difference in kinase activity for
G2019S versus WT LRRK2 is usually ~2 fold greater as reflected by the Vmax values.
The molecular basis for the differences in catalytic rates between using Mg2+ versus Mn2+
are not clear and will require comprehensive structural analysis. However, it is possible
that both metal cations may coordinate the placement and interactions of divalent cationATP in the binding site differently, as such affecting the rate of the phosphoryl-transfer
step. Alternatively, reduced rate of cation-ADP release, which can be a rate limiting step
in protein kinase phosphorylation, may be the major property affected by Mn2+. Indeed,
Lovitt and colleagues have shown that LRRK2 displays a higher affinity for ADP in the
presence of Mn2+ compared to Mg2+ (212).
The dramatic alterations in the catalytic properties of LRRK2 in the presence Mn2+
caused by the G2019S mutation and the greater activity of this mutant is conceptually
consistent with the role of this residue in the active site. G2019 is part of the highly
conserved DFG motif in subdomain VII of the kinase domain (138, 168), and the D
residue in this motif is involved in Mg2+ binding and proper coordination of Mg-ATP in
the active site (67, 170, 200, 315). The relative higher ATP Km, especially in the
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presence of Mn2+, compared to WT LRRK2, suggests that a more rapid exchange of MnATP/ADP at the active site may be partially responsible for the increased catalytic rate of
G2019S LRRK2 in the presence of Mn2+. The DFG motif is located at the N-terminal
hinge region of the activation loop that switches from an open and extended
conformation in the active state to a more closed conformation in the inactive state (67,
168, 315), and this G residue is thought to play an important role in inducing proper
orientation of the D residue (183). After inactivation, the G residue usually performs an
extreme twist, thereby facilitating this D residue to turn away from the catalytic site. The
lack of a side chain is thought to allow the G residue to make this turn with little steric
hindrance. The G2019S mutation may disrupt the ability of this movement, and could
keep the D residue positioned in the active site for longer activation periods that may also
contribute to a greater catalytic rate. Nevertheless, comprehensive structural analyses will
be required to better understand the molecular affects of the G2019S mutation.
The I2020T mutation, which changes the first residue following the DFG-motif, did not
have a dramatic affect on the kinase kinetic properties as did the G2019S mutation.
Nevertheless, consistent with other studies (273) the I2020T mutation demonstrated
significantly reduced ATP Km for ATP.
Studies of the effects of Mg2+ on the observed LRRK2 kinase activity indicate that
increasing the concentration of Mg2+ beyond what is needed to saturate total ATP results
in further activation of LRRK2. Lovitt and colleagues recently reported comparable data
using a truncated version of LRRK2 (LRRK2970-2527)(212). Such an effect has been
observed for several other kinases and in some cases has been attributed to a second Mg2+
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binding site (282, 306). Increasing the concentration of Mg2+ or Mn2+ up to 0.5mM in the
presence of 200µM ATP increases LRRK2 kinase activity, but that is likely
predominantly due to increasing the effective concentration of the cation-ATP complex.
The data from Mn2+/Mg2+ competition assays with G2019S LRRK2 also suggest that
between 0.1-0.5mM, Mn2+ may also promote the kinase activity of LRRK2
independently of increasing Mn-ATP concentration. In contrast to Mg2+, increasing the
concentration of Mn2+ beyond 2mM had an inhibitory affect on LRRK2 kinase activity,
and a similar inhibitory effect observed by Lovitt and colleagues was attributed to
decreased catalytic turnover (212). In our studies, all LRRK2 variants demonstrated
similar relative decreases in activity with increasing Mn2+ beyond 2mM, although for
G2019S LRRK2, kinase activity remained relatively high at all concentrations of Mn2+
compared to WT and other mutants of LRRK2.
These enzymatic kinetic properties of LRRK2 may be more than just interesting in vitro
experiments and may reflect important characteristics of this enzyme that were designed
for biological functionality. Manganese is an essential metal that is widely used in certain
manufacturing industries. Environmental or occupational exposure to high manganese
levels can cause neurotoxicity with the development of a form of parkinsonism known as
manganism (77, 258). Mn2+ is required for many enzymes and its levels in tissue are
usually stable, but it can accumulate in certain brain regions, including the basal ganglia,
following elevated exposure (77, 258). The homeostatic level of free Mn2+ in cells is
maintained by various transporters and by binding to various proteins (12, 77). It is
widely believed that in vivo, Mg2+ is the major ATP cofactor involved in kinase reactions
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because of its higher abundance compared to any other divalent metal cation. However,
given the much greater affinity of LRRK2 for Mn-ATP compared to Mg-ATP (~40 fold
lower Km), and our studies of the effects of sub-stoichiometric concentration of Mn2+ on
Mg2+-mediated LRRK2 kinase activity, it is possible that Mn2+ may act as a potent
inhibitor of LRRK2 kinase activity in vivo. As seen here, in the presence of Mg2+, coincubation with 100 fold lower concentrations of Mn2+ cause a significant reduction in
the kinase activity of WT LRRK2; however this effect does not apply to the G2019S
mutant, where no activity is lost. Therefore, we hypothesize that LRRK2 may act as a
sensor for increased cytoplasmic Mn2+ levels, which results in decreased kinase activity
that would modulate downstream counteractive measures. As a consequence of its
alterations in kinetic properties, it is predicted that the G2019S mutant would remain
largely active at physiologically elevated Mn2+ levels and therefore this putative signaling
pathway should be compromised. Though it can be difficult to directly demonstrate
altered changes in enzyme activity in vivo as a consequence of alterations in specific ion
levels, some in vivo studies have shown that elevated Mn2+ levels can decrease the
activity of some kinases (266). Direct in vivo studies of the proposed model of the
effects of Mn2+ on WT and G2019S LRRK2 kinase activity are complicated by the many
conflicting studies of the effects of LRRK2 on signal transduction pathways and the lack
of robust specific in vivo markers of LRRK2 activity(130), but in vivo studies of Mn2+
affects on LRRK2 kinase activity are currently under investigation. Nevertheless, the
studies described here provide important insights into the kinetic properties of the kinase
activity of LRRK2 and pathogenic mutants as affected by divalent metal cations.
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CHAPTER FIVE
SUMMARY AND FUTURE DIRECTIONS
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The goal of this thesis work was to explore the pathological and biochemical properties
of LRRK2. I have identified and characterized the clinical as well as neuropathological
features of patients with LRRK2 mutations (55, 56, 105). I further examined the effect of
these pathological mutations on the biochemical function of LRRK2 in-vitro to determine
how their aberration may lead to disease (53, 54, 340). I also assessed various factors
that alter LRRK2 kinase activity to understand possible therapeutic intervention points, as
well as models for LRRK2-mediated toxicity.

Patients With LRRK2 Mutations Present with Classical and Nonclassical
Pathology, Regardless of Mutation Location
Despite the strong prevalence of LRRK2 mutations in monogenic forms of PD, only a
handful of cases have come to autopsy. In 2006, we identified and characterized three
patients with LRRK2 mutation (105); however this search was limited in the exons that
were scanned. We expanded the search by including additional regions of the gene, and
in doing so, identified two new patients with LRRK2 mutation from a cohort with
extensive PD and DLB (56).
One subject carried the R793M substitution and presented with typical clinical and
pathological features of PD, while the second was found to have a novel L1165P
substitution, which presented with a more atypical pathology. This patient had an onset
at middle age with a long duration (34 years) and concomitant dementia. Pathologically
this patient presented with an abundance of tau pathology in the hippocampal formation
without SPs (consistent with tangle predominant senile dementia). Of special interest in
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these two patients, but not in our three other G2019S carriers, was the identification of
occasional cytoplasmic TDP-43 inclusions in the temporal cortex.
In addition to the commonality of alpha-synuclein pathology of LRRK2 cases, the
presence of tau pathology in a significant number of patients is notable. Tau pathology is
normally associated with Alzheimer’s disease, however mutations in tau have been
shown to cause nigral loss in frontotemporal dementia with Parkinsonism where TDP-43
inclusions are present (39, 241).

Furthermore, although not generally considered a

pathological component of sporadic forms of PD, a recent GWAS study found gene
association for tau in sporadic PD (82). Given that cases with LRRK2 mutation lead to
disease, and these cases can present with alpha-synuclein and/or tau pathology, it may be
possible that LRRK2 functions upstream of these proteins. Although, complicating a
strict notion that LRRK2 promotes disease through alpha-synculein or tau are cases of
LRRK2 mutation with pure nigral loss in the absence of pathological inclusions (139).
It is not clear why autosomal dominant mutations within LRRK2 present with such a
diverse pathology. LRRK2’s two enzymatically active domains, which are surrounded
by a number of protein-protein and protein-membrane interacting regions, make LRRK2
a prime candidate for its involvement with multiple partners and possible disease
pathways. As previously stated, LRRK2 has been implicated in synpatic endocytosis,
vesicle sorting, and neurite outgrowth and branching.

However, the divergent

pathologies of LRRK2 mutation cannot simply be ascribed to a model of one domain,
one outcome because even patients carrying the same mutation can present with different
pathology (105).
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So the question starts to become, how does LRRK2 confer disease susceptibility? While
the pathology alone of cases is currently insufficient to answer this question, there are
some clues when paired with their genetics. Like alpha-synuclein, LRRK2 follows an
autosomal dominant mode of inheritance. However, unlike multiplications of alphasynuclein, there does not appear to be a dosage effect for LRRK2 mutation.
Homozygotes have the same phenotype with no earlier onset compared to heterozygotes
(158). While this does not rule out a strict gain of function model, it does complicate the
possible mechanisms that LRRK2 mutation may convey toxicity.

A toxic gain of

function is still probable, as is a dominant negative effect. Mutant LRRK2 may pull
binding partners from other pathways, incur changes in substrate specificity and interact
with novel targets, or it may alter the response to a signaling pathway that now leads to
disease. In order to investigate these possibilities, we began to look at the biochemical
properties of these mutations in vitro.

LRRK2 is an Active Kinase that can be Targeted for Possible Therapeutic
Intervention
We created a novel system to purify full-length LRRK2 with active in-vitro kinase
activity (53). Using this system, we assessed the specificity of wildtype and mutant
LRRK2 and found that the G2019S mutation, the most common disease causing
alteration, markedly increased kinase activity.

Given the high prevalence of this

mutation, this highlighted overactive kinase activity as possible intervention point for its
aberrant effects.

To this end, we conducted a screen for molecular inhibitors and

106

identified several compounds that share a basic indolocarbazole structure which act as
potent inhibitors of LRRK2 kinase activity.
Early on, it was shown that LRRK2 expression in cells can lead to neurotoxicity,
contingent upon an active kinase domain (131, 296). While the pathways leading to
disease are still in question, this did establish that the kinase domain could be a critical
target to understand as well as mitigate LRRK2-mediated toxicity. Herein, we were the
first laboratory to publish and characterize a class of compounds capable of inhibiting
LRRK2 kinase activity.
While this list of compounds capable of inhibiting LRRK2 kinase activity been expanded
over the few years since we published our study, it wasn’t until late 2010 that their utility
had been shown in vivo (194). As previously discussed, G2019S transgenic mice do not
show any obvious neuropathological phenotypes, even when expressed 8-16 fold above
endogenous levels (209).

However, this model relied on a tetracycline responsive

Calcium/calmodulin-dependent protein kinase II-alpha (CaMKII) promoter. Dawson and
colleagues recently showed that injection of an HSV amplicon-based G2019S LRRK2
construct directly into the substantia nigra results in inflammation and neurodegeneration
while the wildtype does not (194). Using this model, they were able to show that twice
daily injections of kinase inhibitors attenuated the loss of dopaminergic neurons and the
reduction in density of dopaminergic fibers.
This study provides nice validation to our initial identification of kinase inhibitors,
however their usefulness as a therapeutic for LRRK2-mediated PD still remains in
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question.

While the study does show that this pathogenic mutation can lead to

degeneration within the substantia nigra, it cannot be ascertained if this model would
cause toxicity regardless of where G2019S LRRK2 was expressed, and if this can truly
be representative of pathways involved in pathological LRRK2-mediated PD. Afterall,
mutations outside the kinase domain that have not been shown to have concrete or
substantial effects on kinase activity are linked to disease. This highlights the need to
study how the G2019S mutation may mechanistically lead to degeneration, and what
pathways it may partake in. This is why we began to explore the effects of outside
factors that may augment kinase activity.

The G2019S Mutation May Alter LRRK2 Function, in Addition to Overall
Activity
The effect(s) of LRRK2 pathogenic mutations in vivo remains largely elusive; however,
we have shown that the G2019S pathogenic mutation increases kinase activity, and this
effect has consistently been observed by several other laboratories. As previously stated,
carriers homozygous for the G2019S mutation carry no higher risk, earlier onset, or
greater severity of disease compared to heterozygous carriers.

Therefore, increased

kinase activity of the G2019S mutant alone in the absence of any outside factor is
unlikely to account for the pathogenicity of this mutation. We took a more careful
analysis of LRRK2 kinase activity and found that this mutation, relative to the wildtype
and other pathogenic mutation may act in a novel pathway leading to disease by
disrupting LRRK2 sensitivity to manganese kinase inhibition (54).
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Of various divalent metal cations, only Mg2+ or Mn2+ can support LRRK2 kinase activity.
However, for wild-type, I2020T, and R1441C LRRK2, Mn2+ was significantly less
effective at supporting kinase activity compared to Mg2+. In sharp contrast, both Mn2+
and Mg2+ were effective at supporting the activity of G2019S LRRK2. These divergent
effects associated with divalent cation usage and the G2019S mutation were
predominantly due to differences in catalytic rates. However, LRRK2 was shown to have
a much lower (~40 fold) ATP Km for Mn-ATP compared to Mg-ATP. Consequently,
sub-stoichiometric concentrations of Mn2+ can act to inhibit the kinase activity of wildtype, but not G2019S LRRK2 in the presence of Mg2+. This shows a possible point
where divergent activity could lead directly to toxicity.
Over 75 amino acid substitutions have been found in LRRK2 (60), and the kinase
activating G2019S is the most common (141).

While it’s fairly accepted that this

mutation increases activity and that an active kinase domain is required for neurotoxicity,
no direct correlation of hyperphosphorylated substrates has been found in LRRK2mediated PD. Paired with the absence of any overt neuropathological phenotype in
mouse overexpressing wildtype and mutant forms of LRRK2 (10, 68, 209, 322), as well
the previously mentioned similarity between human heterozygous and homozygous
carriers, suggests that LRRK2 toxicity is not a simple gain of function model. A loss of
function is also unlikely, as the knockout mice develop normally with no overt phenotype
or neuropathology. Any model of LRRK2-mediated toxicity will have to take these
factors into account.
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Our findings for the G2019S LRRK2 mutation, which focus on the disability to regulate
overall kinase activity, implicate a more subtle toxic gain of function. Here, LRRK2 may
act as a censor within the cell, which transduces information through decreased kinase
activity to modulate downstream counteractive measures. As a consequence of its
alterations in kinetic properties, it is predicted that the G2019S mutant would remain
largely active when challenged, and therefore this putative signaling pathway would be
compromised.
Some LRRK2 mutations could also alter signaling pathways through a dominant negative
effect. Given the relatively low kinetic rates published on LRRK2 kinase activity (54,
210, 212, 244, 257, 273), LRRK2 may normally associate with signaling partners through
its kinase domain in a pseduosubstrate fashion. If mutations confer decreased sensitivity
of LRRK2 to cellular stressors, then LRRK2 may still associate with these substrates,
again preventing their participation in downstream counteractive measures.
Given this type of model, it would be interesting to see how the various existing LRRK2
transgenic animals would respond to manganese as well as other cellular stressors. Some
in-vivo data already suggests that LRRK2 may contribute to a protective effect that is lost
upon introduction of mutation. In C. elegans, paraquat treatment results in 98% mortality
at 14 days, however transgenic expression of hLRRK2 rescues this toxicity to only 15%
death, while the G2019S mutant offers no protection(279). Similar effects occur for
rotenone where hLRRK2 mortality drops from 96% to 20%, while the G2019S in this
model protects only at 55%. Disruption of the dLRRK gene in Drosophila can also cause
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enhanced sensitivity to oxidative stress by hydrogen peroxide (337), which is also true for
pathological mutants (Y1383C and I1915T) of dLRRK transgenic flies (157).

Future Directions for Studying LRRK2 in PD
Complicating to setting an overall role for LRRK2 in disease is the diverse and
conflicting biochemical and pathological findings not only in the current thesis work, but
in the overall literature. At the present stage of research, it has been difficult to attribute
a direct mechanism of LRRK2 contribution to disease because of two key factors: (1) a
true physiological substrate has not yet been identified for LRRK2, and (2) it is poorly
understood how outside stressors, environmental toxins, and general upstream factors
may affect LRRK2 activity.
Within our study of LRRK2 specificity, we tested a variety of kinase substrate
recognition motifs and found no activity for LRRK2 outside of the previously identified
ERM phosphorylation consensus sequence. Specificity has also been assessed using a
positional scanning peptide library, however this has provided no physiological substrates
for LRRK2(244). And while a handful of putative substrates have been designated
(alpha-synuclein, beta-tubulin, moesin, 4E-BP), the majority have been disproved, or
remain largely unconfirmed. Currently, there is an absence of physiologically relevant
LRRK2 kinase substrates.
To this end, future efforts should be directed at expanding the search for LRRK2
substrates. Novel substrate identification is difficult as phosphorylation traditionally
occurs at low stoichiometry and on targets expressed at low levels. High-throughput
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screening in the form of peptide microarray libraries allow for the presentation of
substrates at levels detectable by radiometric assay, however this does have two major
drawbacks: (1) it relies on immobilized substrates that may not contain the primary or
secondary structure necessary for kinase recognition, and (2) reactions rely on an in-vitro
kinetic assay that may be missing key cofactors required for proper kinase activity.
There are more intensive methods utilizing chemically tagged ATP analogs that require
remodeling of the ATP binding pocket of the kinase of interest that overcome these
drawbacks (217), however microarray screening has proven to be a valid and productive
starting point for substrate identification.
If, as we have proposed, LRRK2 does activate downstream effectors only in the presence
of certain cofactors, then it will be crucial to test LRRK2 in the presence of these
cofactors as they may augment activity in the above studies.

We have already

demonstrated that manganese can increase affinity by approximately ~40 fold for ATP,
so it will be interesting to see if the use of this divalent cation versus the traditional
magnesium may be useful in identifying novel substrates.
Dimerization also has an increased affect on kinase activity, and recently it has been
shown that LRRK2 can form heterodimers with LRRK1 (61, 176). Currently, no lab has
investigated the effect these heterodimers have on kinase activity or specificity of
LRRK1 or LRRK2.

Given their similar expression patterns and high degree of

homology, it has already been hypothesized that LRRK1 activity may account for the
lack of phenotype in LRRK2 knockout mice (25). Not only may there be overlap in the
pathways of LRRK1 and LRRK2, they may form heterodimers in vivo that have novel
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activity compared to homodimers. Characterizing the activity of these heterodimers may
lead to the identification of novel targets and signaling pathways involved in LRRK2mediated PD.
Besides looking downstream of LRRK2, it is also vital to look upstream to understand
what factors and proteins may affect and interact with LRRK2. Manganese exposure
preferentially causes neurodegeneration of the basal ganglia where LRRK2 is moderately
expressed.

In mouse mesencephalic cultures, manganese exposure at sub-toxic

concentrations results in decreased neurite outgrowth (302), similar to effects seen for
some mutants of LRRK2. Furthermore, like LRRK2, toxic concentrations of manganese
exposure lead to apoptosis through caspase 3 activation (192, 349).

The upstream

proteins that lead to manganese-induced apoptosis have not yet been established,
however, another PD-related protein has been suggested to play a role in this pathway.
(208) Up-regulation of alpha-synuclein occurs at the mRNA and protein level prior to
caspase 3 activation and cell death in SH-SY5Y cells treated with manganese.

In

addition, alpha-synuclein overexpression potentiates manganese-induced apoptosis while
reduced expression through iRNA has a slight but significant protective effect. PARK9
(ATP13A2) has also been linked to manganese as well as alpha-synuclein, where it is
protective for their toxicity in various cellular models (115, 283). Given the similar toxic
effects of mutant LRRK2, manganese, and alpha-synuclein, it may be possible that these
proteins share signaling partners to mediate toxicity. Furthermore, it will be interesting
to see if wildtype LRRK2 has a protective effect in cellular models similar, and whether
it interacts with PARK9.
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Currently, no direct identification of any kinase that may phosphorylate LRRK2 has been
published. The difficulty in tracking substrate phosphorylation within the cell centers
upon the simple fact that all protein kinases utilize ATP, making direct substrate
phosphorylation by a single kinase impossible to track. However, there are methods to
“trap” the kinase responsible by covalently crosslinking the substrate of interest to its
upstream affecter (216). This is accomplished by replacing the targeted T/S/Y residue in
the substrate of interest with a cysteine. This modified substrate can be covalently
crosslinked to the upstream kinase in the presence of chemically modified 5‘fluorosulfonylbenzoyl adenosine (FSBA), a general covalent inhibitor of protein kinases.
This may provide a valuable method to track the upstream effectors of LRRK2
constitutively phosphorylated residues S910 and S935. Recently these residues have
been implicated in binding LRRK2’s interaction with 14-3-3, as well as the stabilization
and dimerization of LRRK2, however the pathway that regulates this activity is unknown
(81, 243).
There are many other aspects of study one could undertake for this complex multidomain protein. Utilizing the information provided in this thesis work should provide
valuable insight and tools for this task.

Given that LRRK2 mutations result in

pathological consequences similar to idiopathic PD, and those mutations in LRRK2 are
the most common known cause of familial and sporadic PD, understanding its
physiological function may provide valuable insights into the development, etiology, and
hopefully treatment of PD.
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